<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29018027</article-id><article-id pub-id-type="pmc">5721886</article-id><article-id pub-id-type="doi">10.1161/JAHA.117.007062</article-id><article-id pub-id-type="publisher-id">JAH32608</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Hypertension</subject></subj-group></subj-group></article-categories><title-group><article-title>Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial</article-title><alt-title alt-title-type="left-running-head">Courand et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah32608-cr-0001" contrib-type="author"><name><surname>Courand</surname><given-names>Pierre&#x02010;Yves</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32608-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32608-cr-0002" contrib-type="author"><name><surname>Pereira</surname><given-names>Helena</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="jah32608-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="jah32608-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah32608-cr-0003" contrib-type="author"><name><surname>Del Giudice</surname><given-names>Costantino</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32608-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32608-cr-0004" contrib-type="author"><name><surname>Gosse</surname><given-names>Philippe</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jah32608-cr-0005" contrib-type="author"><name><surname>Monge</surname><given-names>Matthieu</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jah32608-cr-0006" contrib-type="author"><name><surname>Bobrie</surname><given-names>Guillaume</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32608-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="jah32608-cr-0007" contrib-type="author"><name><surname>Delsart</surname><given-names>Pascal</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32608-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="jah32608-cr-0008" contrib-type="author"><name><surname>Mounier&#x02010;Vehier</surname><given-names>Claire</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="jah32608-cr-0009" contrib-type="author"><name><surname>Lantelme</surname><given-names>Pierre</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah32608-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah32608-cr-0010" contrib-type="author"><name><surname>Denolle</surname><given-names>Thierry</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32608-aff-0010">
<sup>10</sup>
</xref><xref ref-type="aff" rid="jah32608-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="jah32608-cr-0011" contrib-type="author"><name><surname>Dourmap</surname><given-names>Caroline</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32608-aff-0010">
<sup>10</sup>
</xref><xref ref-type="aff" rid="jah32608-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="jah32608-cr-0012" contrib-type="author"><name><surname>Halimi</surname><given-names>Jean Michel</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="jah32608-cr-0013" contrib-type="author"><name><surname>Girerd</surname><given-names>Xavier</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="jah32608-cr-0014" contrib-type="author"><name><surname>Rossignol</surname><given-names>Patrick</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0014">
<sup>14</sup>
</xref></contrib><contrib id="jah32608-cr-0015" contrib-type="author"><name><surname>Zannad</surname><given-names>Faiez</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0014">
<sup>14</sup>
</xref></contrib><contrib id="jah32608-cr-0016" contrib-type="author"><name><surname>Ormezzano</surname><given-names>Olivier</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0015">
<sup>15</sup>
</xref></contrib><contrib id="jah32608-cr-0017" contrib-type="author"><name><surname>Vaisse</surname><given-names>Bernard</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32608-aff-0016">
<sup>16</sup>
</xref></contrib><contrib id="jah32608-cr-0018" contrib-type="author"><name><surname>Herpin</surname><given-names>Daniel</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0017">
<sup>17</sup>
</xref></contrib><contrib id="jah32608-cr-0019" contrib-type="author"><name><surname>Ribstein</surname><given-names>Jean</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0018">
<sup>18</sup>
</xref><xref ref-type="aff" rid="jah32608-aff-0019">
<sup>19</sup>
</xref></contrib><contrib id="jah32608-cr-0020" contrib-type="author"><name><surname>Bouhanick</surname><given-names>Beatrice</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0020">
<sup>20</sup>
</xref></contrib><contrib id="jah32608-cr-0021" contrib-type="author"><name><surname>Mourad</surname><given-names>Jean&#x02010;Jacques</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0021">
<sup>21</sup>
</xref></contrib><contrib id="jah32608-cr-0022" contrib-type="author"><name><surname>Ferrari</surname><given-names>Emile</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0022">
<sup>22</sup>
</xref></contrib><contrib id="jah32608-cr-0023" contrib-type="author"><name><surname>Chatellier</surname><given-names>Gilles</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="jah32608-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah32608-cr-0024" contrib-type="author"><name><surname>Sapoval</surname><given-names>Marc</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah32608-aff-0005">
<sup>5</sup>
</xref><xref ref-type="aff" rid="jah32608-aff-0023">
<sup>23</sup>
</xref></contrib><contrib id="jah32608-cr-0025" contrib-type="author"><name><surname>Azarine</surname><given-names>Arshid</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32608-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah32608-cr-0026" contrib-type="author" corresp="yes"><name><surname>Azizi</surname><given-names>Michel</given-names></name><degrees>MD, PhD</degrees><address><email>michel.azizi@aphp.fr</email></address><xref ref-type="aff" rid="jah32608-aff-0004">
<sup>4</sup>
</xref><xref ref-type="aff" rid="jah32608-aff-0008">
<sup>8</sup>
</xref><xref ref-type="aff" rid="jah32608-aff-0023">
<sup>23</sup>
</xref></contrib><contrib id="jah32608-cr-0027" contrib-type="author"><collab collab-type="authors">the DENERHTN Investigators</collab><xref ref-type="author-notes" rid="jah32608-note-0001">
<sup>&#x02020;</sup>
</xref></contrib></contrib-group><contrib-group><contrib id="jah32608-cr-0028" contrib-type="author"><name><surname>Amar</surname><given-names>L.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0029" contrib-type="author"><name><surname>Bobrie</surname><given-names>G.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0030" contrib-type="author"><name><surname>Lorthioir</surname><given-names>A.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0031" contrib-type="author"><name><surname>Lorthioir</surname><given-names>A.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0032" contrib-type="author"><name><surname>Monge</surname><given-names>M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0033" contrib-type="author"><name><surname>Pagny</surname><given-names>J.&#x02010;Y.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0034" contrib-type="author"><name><surname>Pagny</surname><given-names>J.&#x02010;Y.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0035" contrib-type="author"><name><surname>Plouin</surname><given-names>P. F.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0036" contrib-type="author"><name><surname>Plouin</surname><given-names>P. F.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0037" contrib-type="author"><name><surname>Sapoval</surname><given-names>M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0038" contrib-type="author"><name><surname>Claisse</surname><given-names>G.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0039" contrib-type="author"><name><surname>Delsart</surname><given-names>P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0040" contrib-type="author"><name><surname>Midulla</surname><given-names>M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0041" contrib-type="author"><name><surname>Midulla</surname><given-names>M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0042" contrib-type="author"><name><surname>Mounier&#x02010;Vehier</surname><given-names>C.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0043" contrib-type="author"><name><surname>Courand</surname><given-names>P. Y.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0044" contrib-type="author"><name><surname>Dauphin</surname><given-names>R.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0045" contrib-type="author"><name><surname>Dauphin</surname><given-names>R.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0046" contrib-type="author"><name><surname>Fauvel</surname><given-names>J. P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0047" contrib-type="author"><name><surname>Fauvel</surname><given-names>J. P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0048" contrib-type="author"><name><surname>Lantelme</surname><given-names>P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0049" contrib-type="author"><name><surname>Rouvi&#x000e8;re</surname><given-names>O.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0050" contrib-type="author"><name><surname>Rouvi&#x000e8;re</surname><given-names>O.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0051" contrib-type="author"><name><surname>Cremer</surname><given-names>A.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0052" contrib-type="author"><name><surname>Gosse</surname><given-names>P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0053" contrib-type="author"><name><surname>Grenier</surname><given-names>N.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0054" contrib-type="author"><name><surname>Grenier</surname><given-names>N.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0055" contrib-type="author"><name><surname>Lebras</surname><given-names>Y.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0056" contrib-type="author"><name><surname>Lebras</surname><given-names>Y.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0057" contrib-type="author"><name><surname>Trillaud</surname><given-names>H.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0058" contrib-type="author"><name><surname>Trillaud</surname><given-names>H.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0059" contrib-type="author"><name><surname>Denolle</surname><given-names>T.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0060" contrib-type="author"><name><surname>Dourmap&#x02010;Collas</surname><given-names>C.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0061" contrib-type="author"><name><surname>Dourmap&#x02010;Collas</surname><given-names>C.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0062" contrib-type="author"><name><surname>Heautot</surname><given-names>J. F.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0063" contrib-type="author"><name><surname>Heautot</surname><given-names>J. F.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0064" contrib-type="author"><name><surname>Larralde</surname><given-names>A.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0065" contrib-type="author"><name><surname>Larralde</surname><given-names>A.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0066" contrib-type="author"><name><surname>Paillard</surname><given-names>F.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0067" contrib-type="author"><name><surname>Paillard</surname><given-names>F.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0068" contrib-type="author"><name><surname>Cluzel</surname><given-names>P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0069" contrib-type="author"><name><surname>Girerd</surname><given-names>X.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0070" contrib-type="author"><name><surname>Rosenbaum</surname><given-names>D.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0071" contrib-type="author"><name><surname>Alison</surname><given-names>D.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0072" contrib-type="author"><name><surname>Halimi</surname><given-names>J. M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0073" contrib-type="author"><name><surname>Claudon</surname><given-names>M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0074" contrib-type="author"><name><surname>Popovic</surname><given-names>B.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0075" contrib-type="author"><name><surname>Rossignol</surname><given-names>P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0076" contrib-type="author"><name><surname>Zannad</surname><given-names>F.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0077" contrib-type="author"><name><surname>Baguet</surname><given-names>J. P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0078" contrib-type="author"><name><surname>Ormezzano</surname><given-names>O.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0079" contrib-type="author"><name><surname>Thony</surname><given-names>F.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0080" contrib-type="author"><name><surname>Bartoli</surname><given-names>J. M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0081" contrib-type="author"><name><surname>Va&#x000ef;sse</surname><given-names>B.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0082" contrib-type="author"><name><surname>Drouineau</surname><given-names>J.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0083" contrib-type="author"><name><surname>Herpin</surname><given-names>D.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0084" contrib-type="author"><name><surname>Sosner</surname><given-names>P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0085" contrib-type="author"><name><surname>Tasu</surname><given-names>J. P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0086" contrib-type="author"><name><surname>Velasco</surname><given-names>S.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0087" contrib-type="author"><name><surname>Ribstein</surname><given-names>J.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0088" contrib-type="author"><name><surname>Kovacsik</surname><given-names>H.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0089" contrib-type="author"><name><surname>Bouhanick</surname><given-names>B.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0090" contrib-type="author"><name><surname>Chamontin</surname><given-names>B.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0091" contrib-type="author"><name><surname>Rousseau</surname><given-names>H.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0092" contrib-type="author"><name><surname>Le Jeune</surname><given-names>S.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0093" contrib-type="author"><name><surname>Lopez&#x02010;Sublet</surname><given-names>M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0094" contrib-type="author"><name><surname>Mourad</surname><given-names>J. J.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0095" contrib-type="author"><name><surname>Bellmann</surname><given-names>L.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0096" contrib-type="author"><name><surname>Esnault</surname><given-names>V.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0097" contrib-type="author"><name><surname>Ferrari</surname><given-names>E.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0098" contrib-type="author"><name><surname>Sapoval</surname><given-names>M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0099" contrib-type="author"><name><surname>Bobrie</surname><given-names>G.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0100" contrib-type="author"><name><surname>Chatellier</surname><given-names>G.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0101" contrib-type="author"><name><surname>Plouin</surname><given-names>P. F.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0102" contrib-type="author"><name><surname>Zannad</surname><given-names>F.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0103" contrib-type="author"><name><surname>Halimi</surname><given-names>J. M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0104" contrib-type="author"><name><surname>Baguet</surname><given-names>J. P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0105" contrib-type="author"><name><surname>Kovacsik</surname><given-names>H.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0106" contrib-type="author"><name><surname>Durand&#x02010;Zaleski</surname><given-names>I.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0107" contrib-type="author"><name><surname>Beregi</surname><given-names>J. P.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0108" contrib-type="author"><name><surname>Li&#x000e8;vre</surname><given-names>M.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib><contrib id="jah32608-cr-0109" contrib-type="author"><name><surname>Persu</surname><given-names>A.</given-names></name><xref ref-type="contrib" rid="jah32608-cr-0027"/></contrib></contrib-group><aff id="jah32608-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">H&#x000f4;pital Croix&#x02010;Rousse</named-content>
<named-content content-type="organisation-division">Cardiology Department</named-content>
<named-content content-type="organisation-division">European Society of Hypertension Excellence Centre</named-content>
<institution>Hospices Civils de Lyon</institution>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0002">
<label><sup>2</sup></label>
<institution>CREATIS UMR5220</institution>
<institution>INSERM U1044</institution>
<institution>INSA&#x02010;Lyon</institution>
<institution>Universit&#x000e9; de Lyon</institution>
<institution>Universit&#x000e9; Claude Bernard Lyon 1</institution>
<named-content content-type="city">Lyon</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Clinical Research Unit</named-content>
<institution>Assistance Publique&#x02010;H&#x000f4;pitaux de Paris</institution>
<institution>H&#x000f4;pital Europ&#x000e9;en Georges Pompidou</institution>
<named-content content-type="city">Paris</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0004">
<label><sup>4</sup></label>
<institution>INSERM</institution>
<institution>CIC1418</institution>
<institution>Assistance Publique&#x02010;H&#x000f4;pitaux de Paris</institution>
<institution>H&#x000f4;pital Europ&#x000e9;en Georges Pompidou</institution>
<named-content content-type="city">Paris</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Vascular and Oncological Interventional Radiology Department</named-content>
<institution>Assistance Publique&#x02010;H&#x000f4;pitaux de Paris</institution>
<institution>H&#x000f4;pital Europ&#x000e9;en Georges Pompidou</institution>
<named-content content-type="city">Paris</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Cardiology/Hypertension Department</named-content>
<institution>Centre Hospitalier Universitaire de Bordeaux H&#x000f4;pital Saint Andr&#x000e9;</institution>
<named-content content-type="city">Bordeaux</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0007">
<label><sup>7</sup></label>
<institution>Institut Mutualiste Montsouris</institution>
<named-content content-type="city">Paris</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Hypertension Unit</named-content>
<institution>Assistance Publique&#x02010;H&#x000f4;pitaux de Paris</institution>
<institution>H&#x000f4;pital Europ&#x000e9;en Georges Pompidou</institution>
<named-content content-type="city">Paris</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">H&#x000f4;pital Cardiologique</named-content>
<named-content content-type="organisation-division">M&#x000e9;decine Vasculaire et HTA</named-content>
<institution>Centre Hospitalier R&#x000e9;gional Universitaire de Lille</institution>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0010">
<label><sup>10</sup></label>
<named-content content-type="organisation-division">H&#x000f4;pital Arthur Gardiner</named-content>
<institution>Centre d'excellence en HTA Rennes&#x02010;Dinard</institution>
<named-content content-type="city">Dinard</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0011">
<label><sup>11</sup></label>
<named-content content-type="organisation-division">Service de Cardiologie et Maladies Vasculaires</named-content>
<institution>Centre Hospitalier Universitaire de Rennes</institution>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0012">
<label><sup>12</sup></label>
<institution>H&#x000f4;pital Bretonneau</institution>
<named-content content-type="city">Tours</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0013">
<label><sup>13</sup></label>
<institution>H&#x000f4;pital de la Piti&#x000e9; Salp&#x000e9;tri&#x000e8;re</institution>
<named-content content-type="city">Paris</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0014">
<label><sup>14</sup></label>
<institution>Inserm</institution>
<institution>Centre d'Investigations Cliniques&#x02010;1433</institution>
<institution>Inserm U1116</institution>
<institution>CHRU Nancy</institution>
<institution>F&#x02010;CRIN INI&#x02010;CRCT</institution>
<institution>Universit&#x000e9; de Lorraine</institution>
<named-content content-type="city">Nancy</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0015">
<label><sup>15</sup></label>
<institution>CHU de Grenoble</institution>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0016">
<label><sup>16</sup></label>
<institution>CHU de la Timone</institution>
<named-content content-type="city">Marseille</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0017">
<label><sup>17</sup></label>
<named-content content-type="organisation-division">Cardiology Department</named-content>
<institution>CHU de Poitiers</institution>
<named-content content-type="city">Poitiers</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0018">
<label><sup>18</sup></label>
<institution>H&#x000f4;pital Lapeyronie</institution>
<named-content content-type="city">Montpellier</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0019">
<label><sup>19</sup></label>
<institution>H&#x000f4;pital Arnaud de Villeneuve</institution>
<named-content content-type="city">Montpellier</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0020">
<label><sup>20</sup></label>
<institution>CHU Rangueil</institution>
<named-content content-type="city">Toulouse</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0021">
<label><sup>21</sup></label>
<institution>H&#x000f4;pital Avicenne</institution>
<named-content content-type="city">Bobigny</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0022">
<label><sup>22</sup></label>
<institution>H&#x000f4;pital Pasteur</institution>
<named-content content-type="city">Nice</named-content>
<country country="FR">France</country>
</aff><aff id="jah32608-aff-0023">
<label><sup>23</sup></label>
<institution>Paris&#x02010;Descartes University</institution>
<named-content content-type="city">Paris</named-content>
<country country="FR">France</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Michel Azizi, MD, PhD, INSERM CIC1418 and Hypertension Unit, H&#x000f4;pital Europ&#x000e9;en Georges Pompidou, 20&#x02013;40 rue Leblanc, 75015 Paris, France. E&#x02010;mail: <email>michel.azizi@aphp.fr</email></corresp><fn id="jah32608-note-0001"><label>&#x02020;</label><p>A complete list of investigators in the DENERHTN (Renal Denervation for Hypertension) trial can be found in the Appendix&#x000a0;at the end of the article.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2017</year></pub-date><volume>6</volume><issue>10</issue><issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-10</issue-id><elocation-id>e007062</elocation-id><history><date date-type="received"><day>07</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>15</day><month>8</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e007062.pdf"/><abstract id="jah32608-abs-0001"><sec id="jah32608-sec-0001"><title>Background</title><p>The DENERHTN (Renal Denervation for Hypertension) trial confirmed the efficacy of renal denervation (RDN) in lowering daytime ambulatory systolic blood pressure when added to standardized stepped&#x02010;care antihypertensive treatment (SSAHT) for resistant hypertension at 6&#x000a0;months.</p></sec><sec id="jah32608-sec-0002"><title>Methods and Results</title><p>This post hoc exploratory analysis assessed the impact of abdominal aortic calcifications (AAC) on the hemodynamic and renal response to RDN at 6&#x000a0;months. In total, 106 patients with resistant hypertension were randomly assigned to RDN plus SSAHT or to the same SSAHT alone (control group). Total AAC volume was measured, with semiautomatic software and blind to randomization, from the aortic hiatus to the iliac bifurcation using the prerandomization noncontrast abdominal computed tomography scans of 90 patients. Measurements were expressed as tertiles. The baseline&#x02010;adjusted difference in the change in daytime ambulatory systolic blood pressure from baseline to 6&#x000a0;months between the RDN and control groups was &#x02212;10.1&#x000a0;mm&#x000a0;Hg (<italic>P</italic>=0.0462) in the lowest tertile and &#x02212;2.5&#x000a0;mm&#x000a0;Hg (<italic>P</italic>=0.4987) in the 2 highest tertiles of AAC volume. Estimated glomerular filtration rate remained stable at 6&#x000a0;months for the patients in the lowest tertile of AAC volume who underwent RDN (+2.5&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>) but decreased in the control group (&#x02212;8.0&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>, <italic>P</italic>=0.0148). In the 2 highest tertiles of AAC volume, estimated glomerular filtration rate decreased similarly in the RDN and control groups (<italic>P</italic>=0.2640).</p></sec><sec id="jah32608-sec-0003"><title>Conclusions</title><p>RDN plus SSAHT resulted in a larger decrease in daytime ambulatory systolic blood pressure than SSAHT alone in patients with a lower AAC burden than in those with a higher AAC burden. This larger decrease in daytime ambulatory systolic blood pressure was not associated with a decrease in estimated glomerular filtration rate.</p></sec><sec id="jah32608-sec-0004"><title>Clinical Trial Registration</title><p>URL: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: NCT01570777.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah32608-kwd-0001">antihypertensive therapy/sympathetic nervous system</kwd><kwd id="jah32608-kwd-0002">aortic calcification</kwd><kwd id="jah32608-kwd-0003">aortic disease</kwd><kwd id="jah32608-kwd-0004">atherosclerosis</kwd><kwd id="jah32608-kwd-0005">renal denervation</kwd><kwd id="jah32608-kwd-0006">resistant hypertension</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Hypertension</kwd><kwd>Treatment</kwd><kwd>Vascular Disease</kwd></kwd-group><funding-group><award-group><funding-source>Assistance Publique&#x02010;H&#x000f4;pitaux de Paris</funding-source></award-group><award-group><funding-source>French Ministry of Health</funding-source><award-id>IC110175</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="6"/><page-count count="15"/><word-count count="10118"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah32608</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.1 mode:remove_FC converted:24.10.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah32608-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e007062</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.117.007062">10.1161/JAHA.117.007062</ext-link>.)<pub-id pub-id-type="pmid">29018027</pub-id></mixed-citation>
</p></notes></front><body><p>
<boxed-text position="anchor" content-type="box" id="jah32608-blkfxd-0001" orientation="portrait"><sec id="jah32608-sec-0006"><title>Clinical Perspective</title><sec id="jah32608-sec-0007"><title>What Is New?</title><p>
<list list-type="bullet" id="jah32608-list-0001"><list-item><p>The beneficial blood pressure&#x02013;lowering effect of renal denervation in addition to standardized stepped&#x02010;care antihypertensive treatment is more pronounced in patients with resistant hypertension and a low abdominal aortic calcification burden and is accompanied by stability of estimated glomerular filtration rate.</p></list-item><list-item><p>Conversely, those with a high abdominal aortic calcification burden do not seem to benefit from an additive effect of renal denervation and standardized stepped&#x02010;care antihypertensive treatment.</p></list-item></list>
</p></sec><sec id="jah32608-sec-0008"><title>What Are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah32608-list-0002"><list-item><p>The ambulatory blood pressure reduction with renal denervation is clinically meaningful in patients with low abdominal aortic calcification burden and may help to decrease cardiovascular morbidity and mortality if maintained long term.</p></list-item><list-item><p>Renal denervation may be more effective in younger patients with a low abdominal aortic calcification burden, justifying new clinical trials for milder forms of hypertension.</p></list-item></list>
</p></sec></sec></boxed-text>
</p><sec id="jah32608-sec-0009"><title>Introduction</title><p>The DENERHTN (Renal Denervation for Hypertension) trial showed that renal denervation (RDN) added to standardized stepped&#x02010;care antihypertensive treatment (SSAHT) lowered blood pressure (BP) more effectively than the same SSAHT alone at 6&#x000a0;months in patients with resistant hypertension confirmed by ambulatory BP monitoring.<xref rid="jah32608-bib-0001" ref-type="ref">1</xref> Considerable between&#x02010;patient variability in the BP response was observed in both the RDN and control groups, but this variability was greater in the RDN group than in the control group. Male sex, baseline daytime ambulatory systolic BP (SBP), baseline nighttime ambulatory SBP and its standard deviation, changes in daytime ambulatory heart rate, low treatment score, high adherence to SSHAT were independently associated with the BP response, whereas ethnic origin and the number of ablations were not.<xref rid="jah32608-bib-0001" ref-type="ref">1</xref>, <xref rid="jah32608-bib-0002" ref-type="ref">2</xref>, <xref rid="jah32608-bib-0003" ref-type="ref">3</xref> Nevertheless, identification of predictive factors of BP response to RDN is still necessary to facilitate the selection of patients likely to benefit most from this invasive procedure.<xref rid="jah32608-bib-0004" ref-type="ref">4</xref>, <xref rid="jah32608-bib-0005" ref-type="ref">5</xref>
</p><p>The presence of abdominal aortic calcifications (AAC) is associated with greater aortic stiffness<xref rid="jah32608-bib-0006" ref-type="ref">6</xref>, <xref rid="jah32608-bib-0007" ref-type="ref">7</xref> and a poorer hemodynamic response to antihypertensive drugs.<xref rid="jah32608-bib-0008" ref-type="ref">8</xref> However, it is unknown whether the loss of the viscoelastic and biomechanical properties of the aorta associated with AAC also affects the systemic and renal hemodynamic response to RDN in patients with resistant hypertension. A poorer BP&#x02010;lowering response to RDN has been reported in patients with isolated systolic hypertension (ISH), a condition associated with an increase in arterial stiffness.<xref rid="jah32608-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32608-bib-0010" ref-type="ref">10</xref> In this post hoc analysis of the DENERHTN study, we hypothesized that the presence of AAC may influence the overall hemodynamic and renal response to RDN plus SSAHT and to SSAHT alone.</p></sec><sec id="jah32608-sec-0010"><title>Patients and Methods</title><sec id="jah32608-sec-0011"><title>Study Design</title><p>The design of the DENERHTN trial has been described elsewhere and thus will be summarized only briefly.<xref rid="jah32608-bib-0001" ref-type="ref">1</xref> In this PROBE (prospective randomized open blind end point) trial, patients with confirmed essential resistant hypertension; suitable renal artery anatomy, as evaluated by renal computed tomography (CT) angiogram (n=99) or magnetic resonance imaging (MRI; n=7); and an estimated glomerular filtration rate (eGFR) &#x02265;40&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup> were randomly assigned, in a 1:1 ratio, to the RDN&#x02010;plus&#x02010;SSAHT or the SSAHT&#x02010;alone group. Before randomization, all eligible patients received 1.5&#x000a0;mg slow&#x02010;release indapamide, 10&#x000a0;mg ramipril (or 300&#x000a0;mg irbesartan), and 10&#x000a0;mg amlodipine (or 5&#x000a0;mg) daily for 4&#x000a0;weeks, for the confirmation of resistance to treatment by ambulatory BP monitoring. After randomization, we sequentially added 25 mg spironolactone, 10&#x000a0;mg bisoprolol, 5&#x000a0;mg prazosin, and 1&#x000a0;mg rilmenidine daily from months 2 to 5 in both groups if home BP was &#x02265;135/85&#x000a0;mm&#x000a0;Hg. We performed a median of 11 (interquartile range: 10&#x02013;12) renal nerve ablations per patient, with a Symplicity (Medtronic) single&#x02010;electrode radiofrequency catheter, 2 to 4&#x000a0;weeks after randomization. The primary end point was change in daytime ambulatory SBP at 6&#x000a0;months. The study was approved by the Comit&#x000e9; de Protection des Personnes Ile de France VII (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT01570777). All participants provided written informed consent for participation in the study.</p></sec><sec id="jah32608-sec-0012"><title>CT Scans of the Abdominal Aorta</title><p>We used the renal and abdominal CT angiograms performed before randomization to measure AAC volume. The same imaging parameters were used for all CT scan acquisitions: 2&#x02010;mm slices, 120&#x02010;kV tube voltage, 250&#x02010;mAs tube current, and pitch 0.984. The reconstruction parameters for axial slices were an effective section thickness of 0.8&#x000a0;mm, a 0.4&#x02010;mm increment, and an adapted field of view.</p><p>Only CT scans of the abdominal aorta, not MRI, were used to measure AAC volume. We obtained renal and abdominal 64&#x02010;slice CT scans before and after the injection of contrast agent, in the head&#x02010;to&#x02010;foot direction. Images were obtained for the whole abdominal aorta, from the diaphragm to the iliac bifurcation, and were sent to the imaging core laboratory.</p><p>AACs were detected with a level&#x02010;set method constrained by the Hounsfield units of the delineated structures,<xref rid="jah32608-bib-0011" ref-type="ref">11</xref> as a plaque &#x02265;1&#x000a0;mm<sup>2</sup> in area with a density of &#x0003e;130&#x000a0;Hounsfield units from the aortic hiatus to the iliac bifurcation on noncontrast CT images (Figure&#x000a0;<xref rid="jah32608-fig-0001" ref-type="fig">1</xref>A, 1B, 1B&#x02032;, 1C, and 1C&#x02032;). The total volume of the delineated AAC was then automatically calculated with semiautomatic software (Workstation AW server viewer, version 2.0; GE Medical Systems). Volumes of AAC were not adjusted for calcium density. Patients were classified into tertiles by AAC volume (Figure&#x000a0;<xref rid="jah32608-fig-0001" ref-type="fig">1</xref>D through <xref rid="jah32608-fig-0001" ref-type="fig">1</xref>I). All measurements were performed by a trained radiologist blinded to randomization and the 6&#x02010;month BP results. Within&#x02010; and between&#x02010; observer reproducibility was assessed for AAC volume in a sample of 20 randomly selected patients.</p><fig fig-type="Figure" xml:lang="en" id="jah32608-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Example of aortic calcification segmentation: frontal view of the abdominal aorta (A) and corresponding cross&#x02010;sectional reconstructions at 2 levels: level 1 (B and B&#x02032;) and level 2 (C and C&#x02032;). Native images (B and C) and segmented images (B&#x02032; and C&#x02032;) are provided with an overlay for the calcifications. Three&#x02010;dimensional volume reconstruction for the abdominal aorta of patients, by tertile for abdominal aortic calcification, is shown (D through F), with the results for axial slices (G through I).</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-6-e007062-g001"/></fig></sec><sec id="jah32608-sec-0013"><title>Hemodynamic Assessments</title><p>Supine office BP, 7&#x02010;day seated home BP, and 24&#x02010;hour ambulatory BP (Spacelabs 90207 monitor; Spacelabs Healthcare) measurements were performed before randomization and at 6&#x000a0;months, as described previously.<xref rid="jah32608-bib-0001" ref-type="ref">1</xref> ISH at baseline was defined as a daytime SBP &#x02265;135&#x000a0;mm&#x000a0;Hg and a daytime diastolic BP &#x0003c;85&#x000a0;mm&#x000a0;Hg. Aortic stiffness was estimated through carotid&#x02013;femoral pulse wave velocity (PWV) measured with a Sphygmocor device (AtCor Medical Pty. Ltd; n=82) or with a Complior device (Alam Medical; n=8). PWV was measured over 30&#x000a0;minutes in supine position along the descending thoracoabdominal aorta by the validated foot&#x02010;to&#x02010;foot velocity method (mean of 3 measurements).<xref rid="jah32608-bib-0012" ref-type="ref">12</xref> Real travel distance was used (0.8&#x000d7;direct travel distance) to assess PWV, as recommended.<xref rid="jah32608-bib-0012" ref-type="ref">12</xref> PWV measured with a Complior device was converted using the following formula: PWV Sphygmocor=2.335+1.363&#x000d7;PWV Complior.<xref rid="jah32608-bib-0013" ref-type="ref">13</xref>
</p></sec><sec id="jah32608-sec-0014"><title>Biological Assessments</title><p>We estimated eGFR from plasma creatinine concentration, using the MDRD (Modification of Diet in Renal Disease) formula.<xref rid="jah32608-bib-0014" ref-type="ref">14</xref> Full adherence to SSAHT at 6&#x000a0;months was assessed by determinations of drug concentrations in plasma or urine, as described previously.<xref rid="jah32608-bib-0002" ref-type="ref">2</xref>
</p></sec><sec id="jah32608-sec-0015"><title>Statistical Analyses</title><p>We compared the baseline characteristics of the patients from each tertile for AAC volume by ANOVA and Kruskal&#x02013;Wallis tests, as appropriate, for continuous variables and with the &#x003c7;<sup>2</sup> or Fisher exact test for categorical variables. Paired comparisons were made between tertiles for AAC volume, with Tukey correction for multiple testing on continuous variables and Bonferroni correction for multiple testing on categorical variables.</p><p>We compared the treatment groups (RDN versus control group) at baseline using the unpaired <italic>t</italic> tests or Wilcoxon rank&#x02010;sum tests for continuous variables, or the &#x003c7;<sup>2</sup> or Fisher exact tests for categorical variables. The baseline characteristics of the patients in the second and third tertiles for AAC volume did not differ significantly; therefore, we combined the data for the patients in these 2 tertiles to assess the impact of AAC volume on the BP and renal responses to RDN plus SSAHT and to SSAHT alone. Within each subgroup of patients defined according to tertile for AAC volume (tertiles 2 and 3 and tertile 1), we assessed the effect of treatment on BP parameters and eGFR by ANCOVA, including the baseline value as a covariable, as described previously.<xref rid="jah32608-bib-0001" ref-type="ref">1</xref> Between&#x02010; and within&#x02010;observer reproducibility was assessed for AAC volume measurements by calculating intraclass correlation coefficients and their 95% confidence intervals (CIs).</p><p>Data are presented as mean&#x000b1;SD or median (interquartile range). Mean differences in BP and eGFR between baseline and 6&#x000a0;months are reported, with the 95% CI. We used SAS version 9.4 software (SAS Institute Inc). A <italic>P</italic> value &#x0003c;0.05 was considered significant.</p></sec></sec><sec id="jah32608-sec-0016"><title>Results</title><p>In total, 90 of the 106 patients randomized in the DENERHTN study took part in the CT substudy: 42 of 53 in the RDN group and 48 of 53 in the control group (Figure&#x000a0;<xref rid="jah32608-fig-0002" ref-type="fig">2</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah32608-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Flowchart of the study. No interpretable CT of the abdominal aorta indicates that the patients were evaluated at baseline by magnetic resonance imaging of the abdominal aorta, rather than CT angiogram. ABPM indicates ambulatory blood pressure monitoring; CT, computed tomography; eGFR, estimated glomerular filtration rate.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-6-e007062-g002"/></fig><sec id="jah32608-sec-0017"><title>Clinical, Hemodynamic, and Biological Characteristics of the Patients at Baseline, by Tertile for AAC Volume</title><p>The within&#x02010; and between&#x02010;observer intraclass correlation coefficients for AAC volume measurements were 0.96 (95% CI, 0.90&#x02013;0.98) and 0.90 (95% CI, 0.75&#x02013;0.96), respectively (<italic>P</italic>&#x0003c;0.001 for both). The range of AAC volume was 0 to 11.097&#x000a0;cm<sup>3</sup> in the total patient population (n=90; tertile 1: 0&#x02013;0.122&#x000a0;cm<sup>3</sup>; tertile 2: 0.123&#x02013;1.466&#x000a0;cm<sup>3</sup>; tertile 3: 1.467&#x02013;11.097&#x000a0;cm<sup>3</sup>). Nineteen of the 30 patients in tertile 1 (66%) had no visible AAC on CT scans.</p><p>The patients in the upper 2 tertiles for AAC volume were significantly older and more likely to smoke and to have type 2 diabetes mellitus, hyperlipidemia, ISH, and obstructive sleep apnea than the patients in tertile 1 (Table&#x000a0;<xref rid="jah32608-tbl-0001" ref-type="table-wrap">1</xref>). They were also more likely to be male and white, with a history of cardiovascular events, including stroke, lower eGFR, and higher urinary albumin:creatinine ratio. The patients in the second and third tertiles for AAC volume had the highest daytime and 24&#x02010;hour ambulatory pulse pressure and PWV, with no difference between these 2 subgroups (Table&#x000a0;<xref rid="jah32608-tbl-0001" ref-type="table-wrap">1</xref>). A similar but nonsignificant trend was observed for all other hemodynamic parameters.</p><table-wrap id="jah32608-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical and Biological Characteristics of Patients in the Entire Cohort and by Tertile for AAC Volume at Baseline</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">First Tertile 0&#x02013;122&#x000a0;mm<sup>3</sup>
</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Second Tertile 123&#x02013;1466&#x000a0;mm<sup>3</sup>
</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Third Tertile 1467&#x02013;11&#x000a0;097&#x000a0;mm<sup>3</sup>
</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value<xref ref-type="fn" rid="jah32608-note-0003">a</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">n=30</th><th align="left" valign="top" rowspan="1" colspan="1">n=30</th><th align="left" valign="top" rowspan="1" colspan="1">n=30</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Clinical characteristics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">45.7&#x000b1;8.2<xref ref-type="fn" rid="jah32608-note-0004">b</xref>, <xref ref-type="fn" rid="jah32608-note-0005">c</xref>
</td><td align="left" rowspan="1" colspan="1">55.6&#x000b1;6.6<xref ref-type="fn" rid="jah32608-note-0005">c</xref>
</td><td align="left" rowspan="1" colspan="1">62.3&#x000b1;9.5</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">13 (43.3)</td><td align="left" rowspan="1" colspan="1">21 (70.0)</td><td align="left" rowspan="1" colspan="1">21 (70.0)</td><td align="left" rowspan="1" colspan="1">0.0502</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">23 (76.7)</td><td align="left" rowspan="1" colspan="1">19 (63.3)</td><td align="left" rowspan="1" colspan="1">27 (90.0)</td><td align="left" rowspan="1" colspan="1">0.0579</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current or former smokers</td><td align="left" rowspan="1" colspan="1">9 (30.0)<xref ref-type="fn" rid="jah32608-note-0005">c</xref>
</td><td align="left" rowspan="1" colspan="1">14 (46.7)</td><td align="left" rowspan="1" colspan="1">23 (76.7)</td><td align="left" rowspan="1" colspan="1">0.0012</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Type 2 diabetes mellitus</td><td align="left" rowspan="1" colspan="1">0 (0.0)<xref ref-type="fn" rid="jah32608-note-0004">b</xref>, <xref ref-type="fn" rid="jah32608-note-0005">c</xref>
</td><td align="left" rowspan="1" colspan="1">9 (30.0)</td><td align="left" rowspan="1" colspan="1">11 (36.7)</td><td align="left" rowspan="1" colspan="1">0.0003</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperlipidemia</td><td align="left" rowspan="1" colspan="1">8 (26.7)<xref ref-type="fn" rid="jah32608-note-0005">c</xref>
</td><td align="left" rowspan="1" colspan="1">13 (43.3)</td><td align="left" rowspan="1" colspan="1">18 (60.0)</td><td align="left" rowspan="1" colspan="1">0.0336</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior cardiovascular event</td><td align="left" rowspan="1" colspan="1">3 (10.0)</td><td align="left" rowspan="1" colspan="1">8 (26.7)</td><td align="left" rowspan="1" colspan="1">10 (33.3)</td><td align="left" rowspan="1" colspan="1">0.0832</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior stroke</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">4 (13.3)</td><td align="left" rowspan="1" colspan="1">4 (13.3)</td><td align="left" rowspan="1" colspan="1">0.1195</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Obstructive sleep apnea</td><td align="left" rowspan="1" colspan="1">5 (16.7)</td><td align="left" rowspan="1" colspan="1">8 (26.7)</td><td align="left" rowspan="1" colspan="1">14 (46.7)</td><td align="left" rowspan="1" colspan="1">0.0422</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">30.8&#x000b1;5.1</td><td align="left" rowspan="1" colspan="1">29.8&#x000b1;4.4</td><td align="left" rowspan="1" colspan="1">30.8&#x000b1;5.0</td><td align="left" rowspan="1" colspan="1">0.6616</td></tr><tr><td align="left" colspan="5" rowspan="1">Biological characteristics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Plasma creatinine, &#x003bc;mol/L</td><td align="left" rowspan="1" colspan="1">77.4&#x000b1;26.9</td><td align="left" rowspan="1" colspan="1">85.7&#x000b1;19.5</td><td align="left" rowspan="1" colspan="1">86.9&#x000b1;23.6</td><td align="left" rowspan="1" colspan="1">0.2435</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">eGFR, mL/min/1.73&#x000a0;m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">98.2&#x000b1;26.2</td><td align="left" rowspan="1" colspan="1">87.8&#x000b1;17.6</td><td align="left" rowspan="1" colspan="1">83.8&#x000b1;27.0</td><td align="left" rowspan="1" colspan="1">0.0643</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">UACR, mg/mmol<xref ref-type="fn" rid="jah32608-note-0006">d</xref>
</td><td align="left" rowspan="1" colspan="1">0.7 (0.5&#x02013;1.8)<xref ref-type="fn" rid="jah32608-note-0005">c</xref>
</td><td align="left" rowspan="1" colspan="1">1.1 (0.4&#x02013;4.0)</td><td align="left" rowspan="1" colspan="1">3.0 (1.1&#x02013;7.5)</td><td align="left" rowspan="1" colspan="1">0.0264</td></tr><tr><td align="left" colspan="5" rowspan="1">Hemodynamic parameters</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Office SBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">151.4&#x000b1;20.7</td><td align="left" rowspan="1" colspan="1">157.7&#x000b1;19.7</td><td align="left" rowspan="1" colspan="1">162.0&#x000b1;22.3</td><td align="left" rowspan="1" colspan="1">0.1500</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Office DBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">94.7&#x000b1;15.1</td><td align="left" rowspan="1" colspan="1">92.1&#x000b1;13.0</td><td align="left" rowspan="1" colspan="1">90.3&#x000b1;14.6</td><td align="left" rowspan="1" colspan="1">0.4784</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Office HR, beats/min</td><td align="left" rowspan="1" colspan="1">72.9&#x000b1;10.3</td><td align="left" rowspan="1" colspan="1">71.0&#x000b1;11.8</td><td align="left" rowspan="1" colspan="1">73.4&#x000b1;11.7</td><td align="left" rowspan="1" colspan="1">0.7134</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Daytime ambulatory SBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">150.4&#x000b1;17.2</td><td align="left" rowspan="1" colspan="1">154.4&#x000b1;15.4</td><td align="left" rowspan="1" colspan="1">155.7&#x000b1;17.0</td><td align="left" rowspan="1" colspan="1">0.4444</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Daytime ambulatory DBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">95.8&#x000b1;12.5</td><td align="left" rowspan="1" colspan="1">91.4&#x000b1;13.9</td><td align="left" rowspan="1" colspan="1">91.3&#x000b1;13.4</td><td align="left" rowspan="1" colspan="1">0.3292</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Daytime ambulatory PP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">54.6&#x000b1;9.2<xref ref-type="fn" rid="jah32608-note-0004">b</xref>, <xref ref-type="fn" rid="jah32608-note-0005">c</xref>
</td><td align="left" rowspan="1" colspan="1">63.1&#x000b1;14.0</td><td align="left" rowspan="1" colspan="1">64.3&#x000b1;16.6</td><td align="left" rowspan="1" colspan="1">0.0140</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nighttime ambulatory SBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">136.2&#x000b1;16.5</td><td align="left" rowspan="1" colspan="1">140.6&#x000b1;17.2</td><td align="left" rowspan="1" colspan="1">140.7&#x000b1;15.7</td><td align="left" rowspan="1" colspan="1">0.4903</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nighttime ambulatory DBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">82.8&#x000b1;12.2</td><td align="left" rowspan="1" colspan="1">80.8&#x000b1;15.0</td><td align="left" rowspan="1" colspan="1">80.3&#x000b1;14.5</td><td align="left" rowspan="1" colspan="1">0.7682</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nighttime ambulatory PP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">53.5&#x000b1;8.4</td><td align="left" rowspan="1" colspan="1">59.7&#x000b1;13.1</td><td align="left" rowspan="1" colspan="1">60.5&#x000b1;16.0</td><td align="left" rowspan="1" colspan="1">0.0747</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x02010;h ambulatory SBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">146.8&#x000b1;16.7</td><td align="left" rowspan="1" colspan="1">150.5&#x000b1;15.9</td><td align="left" rowspan="1" colspan="1">151.6&#x000b1;16.2</td><td align="left" rowspan="1" colspan="1">0.4924</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x02010;h ambulatory DBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">92.8&#x000b1;12.3</td><td align="left" rowspan="1" colspan="1">88.4&#x000b1;14.0</td><td align="left" rowspan="1" colspan="1">88.4&#x000b1;13.6</td><td align="left" rowspan="1" colspan="1">0.3451</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x02010;h ambulatory PP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">54.1&#x000b1;8.7<xref ref-type="fn" rid="jah32608-note-0005">c</xref>
</td><td align="left" rowspan="1" colspan="1">62.1&#x000b1;13.8</td><td align="left" rowspan="1" colspan="1">63.2&#x000b1;16.1</td><td align="left" rowspan="1" colspan="1">0.0171</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PWV, m/s</td><td align="left" rowspan="1" colspan="1">9.7&#x000b1;2.2<xref ref-type="fn" rid="jah32608-note-0004">b</xref>, <xref ref-type="fn" rid="jah32608-note-0005">c</xref>
</td><td align="left" rowspan="1" colspan="1">11.6&#x000b1;2.8</td><td align="left" rowspan="1" colspan="1">12.8&#x000b1;2.8</td><td align="left" rowspan="1" colspan="1">0.0004</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Isolated systolic hypertension</td><td align="left" rowspan="1" colspan="1">5 (16.7)</td><td align="left" rowspan="1" colspan="1">9 (30.0)</td><td align="left" rowspan="1" colspan="1">9 (30.0)</td><td align="left" rowspan="1" colspan="1">0.4267</td></tr></tbody></table><table-wrap-foot><fn id="jah32608-note-0002"><p>Data are expressed as mean&#x000b1;SD, n (%), or median (interquartile range). AAC indicates abdominal aortic calcification; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HR, heart rate; PP, pulse pressure; PWV, pulse wave velocity; SBP, systolic blood pressure; UACR, urinary albumin:creatinine ratio. Isolated systolic hypertension on ambulatory blood pressure monitoring was defined as daytime ambulatory SBP &#x02265;135&#x000a0;mm&#x000a0;Hg and DBP &#x0003c;85&#x000a0;mm&#x000a0;Hg.</p></fn><fn id="jah32608-note-0003"><label>a</label><p>
<italic>P</italic> values by ANOVA and Kruskal&#x02013;Wallis tests for continuous variables and by &#x003c7;<sup>2</sup> and Fisher exact tests for categorical variables.</p></fn><fn id="jah32608-note-0004"><label>b</label><p>
<italic>P</italic>&#x0003c;0.05 vs second tertile.</p></fn><fn id="jah32608-note-0005"><label>c</label><p>
<italic>P</italic>&#x0003c;0.05 vs third tertile.</p></fn><fn id="jah32608-note-0006"><label>d</label><p>n=26, n=26, and n=24 for tertiles 1, 2 and 3, respectively (total: 76 measurements).</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah32608-sec-0018"><title>BP Response to RDN Plus SSAHT and SSAHT Alone at 6&#x000a0;Months by Tertile for AAC Volume</title><p>Regardless of tertile for AAC volume, there were no significant differences in baseline characteristics between the RDN and control groups (Table&#x000a0;<xref rid="jah32608-tbl-0002" ref-type="table-wrap">2</xref>), and these characteristics were similar to those previously reported for the DENERHTN study.<xref rid="jah32608-bib-0001" ref-type="ref">1</xref> The median volume of AAC did not significantly differ between the RDN and control groups, but there was considerable between&#x02010;patient variability in AAC volume (0.448 cm<sup>3</sup> [interquartile range: 0.098&#x02013;2.055 cm<sup>3</sup>] versus 0.433 cm<sup>3</sup> [interquartile range: 0.012&#x02013;2.310 cm<sup>3</sup>], respectively; Table&#x000a0;<xref rid="jah32608-tbl-0002" ref-type="table-wrap">2</xref>). We previously showed that at 6&#x000a0;months follow&#x02010;up, RDN combined with a median number of 5 drugs of the SSAHT significantly reduced daytime (primary end point), nighttime, and 24&#x02010;hour ambulatory SBP by &#x02248;6&#x000a0;mm&#x02009;Hg more than with 5 drugs of the SSAHT alone, regardless of AAC volume tertile.<xref rid="jah32608-bib-0001" ref-type="ref">1</xref> The proportion of patients with full adherence to the SSAHT at 6&#x000a0;months did not differ significantly between the 2 groups (51.3% for RDN group versus : 50.0% for control group; <italic>P</italic>=0.9093).</p><table-wrap id="jah32608-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline Comparison of the RDN and Control Groups in the CT Angiogram Substudy</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">All</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">RDN</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Control</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value<xref ref-type="fn" rid="jah32608-note-0008">a</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">n=90</th><th align="left" valign="top" rowspan="1" colspan="1">n=42</th><th align="left" valign="top" rowspan="1" colspan="1">n=48</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Clinical characteristics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">54.6&#x000b1;10.6</td><td align="left" rowspan="1" colspan="1">54.5&#x000b1;11.1</td><td align="left" rowspan="1" colspan="1">54.6&#x000b1;10.3</td><td align="left" rowspan="1" colspan="1">0.9817</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">55 (61.1)</td><td align="left" rowspan="1" colspan="1">26 (61.9)</td><td align="left" rowspan="1" colspan="1">29 (60.4)</td><td align="left" rowspan="1" colspan="1">0.8851</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">69 (76.7)</td><td align="left" rowspan="1" colspan="1">33 (78.6)</td><td align="left" rowspan="1" colspan="1">36 (75.0)</td><td align="left" rowspan="1" colspan="1">0.6894</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nonsmokers</td><td align="left" rowspan="1" colspan="1">44 (48.9)</td><td align="left" rowspan="1" colspan="1">20 (47.6)</td><td align="left" rowspan="1" colspan="1">24 (50.0)</td><td align="left" rowspan="1" colspan="1">0.3373</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Type 2 diabetes mellitus</td><td align="left" rowspan="1" colspan="1">20 (22.2)</td><td align="left" rowspan="1" colspan="1">7 (16.7)</td><td align="left" rowspan="1" colspan="1">13 (27.1)</td><td align="left" rowspan="1" colspan="1">0.2357</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperlipidemia</td><td align="left" rowspan="1" colspan="1">39 (43.3)</td><td align="left" rowspan="1" colspan="1">19 (45.2)</td><td align="left" rowspan="1" colspan="1">20 (41.7)</td><td align="left" rowspan="1" colspan="1">0.7330</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior cardiovascular event</td><td align="left" rowspan="1" colspan="1">21 (23.3)</td><td align="left" rowspan="1" colspan="1">13 (31.0)</td><td align="left" rowspan="1" colspan="1">8 (16.7)</td><td align="left" rowspan="1" colspan="1">0.1099</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior stoke</td><td align="left" rowspan="1" colspan="1">8 (8.9)</td><td align="left" rowspan="1" colspan="1">5 (11.9)</td><td align="left" rowspan="1" colspan="1">3 (6.3)</td><td align="left" rowspan="1" colspan="1">0.4654</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Obstructive sleep apnea</td><td align="left" rowspan="1" colspan="1">27 (30.0)</td><td align="left" rowspan="1" colspan="1">14 (33.3)</td><td align="left" rowspan="1" colspan="1">13 (27.1)</td><td align="left" rowspan="1" colspan="1">0.5186</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">30.5&#x000b1;4.8</td><td align="left" rowspan="1" colspan="1">30.8&#x000b1;5.2</td><td align="left" rowspan="1" colspan="1">30.2&#x000b1;4.4</td><td align="left" rowspan="1" colspan="1">0.5307</td></tr><tr><td align="left" colspan="5" rowspan="1">Biological characteristics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Plasma creatinine, &#x003bc;mol/L</td><td align="left" rowspan="1" colspan="1">83.4&#x000b1;23.6</td><td align="left" rowspan="1" colspan="1">83.2&#x000b1;22.7</td><td align="left" rowspan="1" colspan="1">83.6&#x000b1;24.6</td><td align="left" rowspan="1" colspan="1">0.9481</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">eGFR, mL/min/1.73&#x000a0;m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">89.8&#x000b1;24.5</td><td align="left" rowspan="1" colspan="1">89.9&#x000b1;25.2</td><td align="left" rowspan="1" colspan="1">89.8&#x000b1;24.1</td><td align="left" rowspan="1" colspan="1">0.9845</td></tr><tr><td align="left" colspan="5" rowspan="1">Cardiovascular parameters</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Office SBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">157.0&#x000b1;21.1</td><td align="left" rowspan="1" colspan="1">159.0&#x000b1;22.1</td><td align="left" rowspan="1" colspan="1">155.3&#x000b1;20.3</td><td align="left" rowspan="1" colspan="1">0.4023</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Office DBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">92.3&#x000b1;14.2</td><td align="left" rowspan="1" colspan="1">94.0&#x000b1;15.1</td><td align="left" rowspan="1" colspan="1">90.9&#x000b1;13.4</td><td align="left" rowspan="1" colspan="1">0.3140</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Office HR, beats/min</td><td align="left" rowspan="1" colspan="1">72.4&#x000b1;11.2</td><td align="left" rowspan="1" colspan="1">71.5&#x000b1;10.6</td><td align="left" rowspan="1" colspan="1">73.2&#x000b1;11.8</td><td align="left" rowspan="1" colspan="1">0.4691</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Daytime ambulatory SBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">153.5&#x000b1;16.5</td><td align="left" rowspan="1" colspan="1">155.9&#x000b1;16.7</td><td align="left" rowspan="1" colspan="1">151.4&#x000b1;16.2</td><td align="left" rowspan="1" colspan="1">0.1960</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Daytime ambulatory DBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">92.8&#x000b1;13.3</td><td align="left" rowspan="1" colspan="1">93.5&#x000b1;15.6</td><td align="left" rowspan="1" colspan="1">92.3&#x000b1;11.1</td><td align="left" rowspan="1" colspan="1">0.6816</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Daytime ambulatory PP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">60.7&#x000b1;14.2</td><td align="left" rowspan="1" colspan="1">62.5&#x000b1;14.3</td><td align="left" rowspan="1" colspan="1">59.1&#x000b1;14.0</td><td align="left" rowspan="1" colspan="1">0.2619</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nighttime ambulatory SBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">139.2&#x000b1;16.4</td><td align="left" rowspan="1" colspan="1">142.8&#x000b1;17.7</td><td align="left" rowspan="1" colspan="1">136.0&#x000b1;14.7</td><td align="left" rowspan="1" colspan="1">0.0478</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nighttime ambulatory DBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">81.3&#x000b1;13.8</td><td align="left" rowspan="1" colspan="1">83.4&#x000b1;16.4</td><td align="left" rowspan="1" colspan="1">79.4&#x000b1;10.9</td><td align="left" rowspan="1" colspan="1">0.1715</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nighttime ambulatory PP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">57.9&#x000b1;13.1</td><td align="left" rowspan="1" colspan="1">59.4&#x000b1;12.9</td><td align="left" rowspan="1" colspan="1">56.6&#x000b1;13.4</td><td align="left" rowspan="1" colspan="1">0.3082</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x02010;h ambulatory SBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">149.7&#x000b1;16.2</td><td align="left" rowspan="1" colspan="1">152.4&#x000b1;16.9</td><td align="left" rowspan="1" colspan="1">147.3&#x000b1;15.4</td><td align="left" rowspan="1" colspan="1">0.1400</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x02010;h ambulatory DBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">89.9&#x000b1;13.3</td><td align="left" rowspan="1" colspan="1">90.8&#x000b1;15.7</td><td align="left" rowspan="1" colspan="1">89.0&#x000b1;10.9</td><td align="left" rowspan="1" colspan="1">0.5178</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x02010;h ambulatory PP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">59.8&#x000b1;13.7</td><td align="left" rowspan="1" colspan="1">61.5&#x000b1;13.7</td><td align="left" rowspan="1" colspan="1">58.3&#x000b1;13.7</td><td align="left" rowspan="1" colspan="1">0.2675</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PWV, m/s</td><td align="left" rowspan="1" colspan="1">11.3&#x000b1;2.9</td><td align="left" rowspan="1" colspan="1">11.7&#x000b1;2.8</td><td align="left" rowspan="1" colspan="1">11.0&#x000b1;3.0</td><td align="left" rowspan="1" colspan="1">0.2964</td></tr><tr><td align="left" colspan="5" rowspan="1">AAC, cm<sup>3</sup>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.448 (0.098&#x02013;2.055)</td><td align="left" rowspan="1" colspan="1">0.433 (0.012&#x02013;2.310)</td><td align="left" rowspan="1" colspan="1">0.7954</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tertile 1</td><td align="left" rowspan="1" colspan="1">30 (33.3)</td><td align="left" rowspan="1" colspan="1">13 (31.0)</td><td align="left" rowspan="1" colspan="1">17 (35.4)</td><td align="left" rowspan="1" colspan="1">0.3916</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tertile 2</td><td align="left" rowspan="1" colspan="1">30 (33.3)</td><td align="left" rowspan="1" colspan="1">17 (40.5)</td><td align="left" rowspan="1" colspan="1">13 (27.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tertile 3</td><td align="left" rowspan="1" colspan="1">30 (33.3)</td><td align="left" rowspan="1" colspan="1">12 (28.6)</td><td align="left" rowspan="1" colspan="1">18 (37.5)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="jah32608-note-0007"><p>Data are expressed as mean&#x000b1;SD, n (%), or median (interquartile range). AAC indicates abdominal aortic calcifications; BMI, body mass index; CT, computed tomography; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HR, heart rate; PP, pulse pressure; PWV, pulse wave velocity; RDN, renal denervation; SBP, systolic blood pressure.</p></fn><fn id="jah32608-note-0008"><label>a</label><p>
<italic>P</italic> values were obtained by unpaired <italic>t</italic> tests and Mann&#x02013;Whitney <italic>U</italic> tests for continuous variables and by &#x003c7;<sup>2</sup> and Fisher exact tests for discrete variables.</p></fn></table-wrap-foot></table-wrap><p>Two contrasting patterns were observed in the analysis of BP response by AAC volume tertile. Indeed, the baseline&#x02010;adjusted difference in the change in daytime ambulatory SBP from baseline to 6&#x000a0;months between the RDN and control groups was &#x02212;10.1&#x000a0;mm&#x000a0;Hg (95% CI, &#x02212;20.0 to &#x02212;0.2&#x000a0;mm&#x000a0;Hg, <italic>P=</italic>0.0462) for the patients in tertile 1 but only &#x02212;2.5&#x000a0;mm&#x000a0;Hg (95% CI, &#x02212;9.9 to 4.9&#x000a0;mm&#x000a0;Hg, <italic>P</italic>=0.4987) for the patients in combined tertiles 2 and 3 (Table&#x000a0;<xref rid="jah32608-tbl-0003" ref-type="table-wrap">3</xref>). A similar but nonsignificant trend was observed for the baseline&#x02010;adjusted difference in the change in nighttime and 24&#x02010;hour ambulatory SBP according to AAC volume tertile (Table&#x000a0;<xref rid="jah32608-tbl-0003" ref-type="table-wrap">3</xref>). Changes in daytime ambulatory SBP from baseline are shown in Figure&#x000a0;<xref rid="jah32608-fig-0003" ref-type="fig">3</xref>. We observed no significant difference in the change from baseline to 6&#x000a0;months for ambulatory diastolic BP and heart rate between the RDN and control groups, according to AAC volume tertile (Tables&#x000a0;<xref rid="jah32608-tbl-0004" ref-type="table-wrap">4</xref> and <xref rid="jah32608-tbl-0005" ref-type="table-wrap">5</xref>).</p><table-wrap id="jah32608-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>ASBP at Randomization and After 6&#x02010;Mo Follow&#x02010;up by Tertile for AAC Volume in the RDN and Control Groups</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">RDN Group</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Control Group</th><th align="left" rowspan="2" valign="top" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI) Between the 2 Groups at 6&#x000a0;Mo<xref ref-type="fn" rid="jah32608-note-0010">a</xref>
</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Randomization (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;Mo (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">Randomization (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;Mo (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1">Tertile 1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ASBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">(n=13)</td><td align="left" rowspan="1" colspan="1">(n=13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n=17)</td><td align="left" rowspan="1" colspan="1">(n=17)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Daytime</td><td align="left" rowspan="1" colspan="1">154.0&#x000b1;17.5</td><td align="left" rowspan="1" colspan="1">135.1&#x000b1;12.6</td><td align="left" rowspan="1" colspan="1">&#x02212;17.6 (&#x02212;25.0 to &#x02212;10.2)</td><td align="left" rowspan="1" colspan="1">147.7&#x000b1;16.9</td><td align="left" rowspan="1" colspan="1">141.2&#x000b1;19.2</td><td align="left" rowspan="1" colspan="1">&#x02212;7.5 (&#x02212;14.0 to &#x02212;1.1)</td><td align="left" rowspan="1" colspan="1">&#x02212;10.1 (&#x02212;20.0 to &#x02212;0.2)</td><td align="left" rowspan="1" colspan="1">0.0462</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Nighttime</td><td align="left" rowspan="1" colspan="1">142.8&#x000b1;18.8</td><td align="left" rowspan="1" colspan="1">126.4&#x000b1;11.0</td><td align="left" rowspan="1" colspan="1">&#x02212;13.5 (&#x02212;21.8 to &#x02212;5.2)</td><td align="left" rowspan="1" colspan="1">131.2&#x000b1;12.8</td><td align="left" rowspan="1" colspan="1">122.9&#x000b1;19.4</td><td align="left" rowspan="1" colspan="1">&#x02212;10.5 (&#x02212;17.7 to &#x02212;3.3)</td><td align="left" rowspan="1" colspan="1">&#x02212;3.1 (&#x02212;14.4 to 8.3)</td><td align="left" rowspan="1" colspan="1">0.5828</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">24&#x02010;h</td><td align="left" rowspan="1" colspan="1">151.2&#x000b1;17.9</td><td align="left" rowspan="1" colspan="1">132.8&#x000b1;11.8</td><td align="left" rowspan="1" colspan="1">&#x02212;16.7 (&#x02212;24 to &#x02212;9.3)</td><td align="left" rowspan="1" colspan="1">143.5&#x000b1;15.4</td><td align="left" rowspan="1" colspan="1">136.6&#x000b1;18.8</td><td align="left" rowspan="1" colspan="1">&#x02212;8.2 (&#x02212;14.6 to &#x02212;1.8)</td><td align="left" rowspan="1" colspan="1">&#x02212;8.5 (&#x02212;18.4 to 1.5)</td><td align="left" rowspan="1" colspan="1">0.0921</td></tr><tr><td align="left" colspan="9" rowspan="1">Tertiles 2 and 3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ASBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">(n=29)</td><td align="left" rowspan="1" colspan="1">(n=29)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n=31)</td><td align="left" rowspan="1" colspan="1">(n=31)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Daytime</td><td align="left" rowspan="1" colspan="1">156.8&#x000b1;16.6</td><td align="left" rowspan="1" colspan="1">141.9&#x000b1;20.5</td><td align="left" rowspan="1" colspan="1">&#x02212;14.5 (&#x02212;19.8 to &#x02212;9.2)</td><td align="left" rowspan="1" colspan="1">153.4&#x000b1;15.7</td><td align="left" rowspan="1" colspan="1">141.8&#x000b1;17.0</td><td align="left" rowspan="1" colspan="1">&#x02212;12 (&#x02212;17.1 to &#x02212;6.8)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.5 (&#x02212;9.9 to 4.9)</td><td align="left" rowspan="1" colspan="1">0.4987</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Nighttime</td><td align="left" rowspan="1" colspan="1">142.9&#x000b1;17.6</td><td align="left" rowspan="1" colspan="1">128.8&#x000b1;21.8</td><td align="left" rowspan="1" colspan="1">&#x02212;13.7 (&#x02212;19.2 to &#x02212;8.2)</td><td align="left" rowspan="1" colspan="1">138.6&#x000b1;15.1</td><td align="left" rowspan="1" colspan="1">132.4&#x000b1;17.4</td><td align="left" rowspan="1" colspan="1">&#x02212;6.6 (&#x02212;12.0 to &#x02212;1.3)</td><td align="left" rowspan="1" colspan="1">&#x02212;7.0 (&#x02212;14.7 to 0.7)</td><td align="left" rowspan="1" colspan="1">0.0729</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">24&#x02010;h</td><td align="left" rowspan="1" colspan="1">152.9&#x000b1;16.7</td><td align="left" rowspan="1" colspan="1">137.9&#x000b1;20.6</td><td align="left" rowspan="1" colspan="1">&#x02212;14.6 (&#x02212;19.6 to &#x02212;9.6)</td><td align="left" rowspan="1" colspan="1">149.4&#x000b1;15.3</td><td align="left" rowspan="1" colspan="1">139.0&#x000b1;15.9</td><td align="left" rowspan="1" colspan="1">&#x02212;10.7 (&#x02212;15.6 to &#x02212;5.9)</td><td align="left" rowspan="1" colspan="1">&#x02212;3.8 (&#x02212;10.8 to 3.1)</td><td align="left" rowspan="1" colspan="1">0.2730</td></tr></tbody></table><table-wrap-foot><fn id="jah32608-note-0009"><p>AAC indicates abdominal aortic calcifications; ASBP, ambulatory systolic blood pressure; CI, confidence interval; RDN, renal denervation.</p></fn><fn id="jah32608-note-0010"><label>a</label><p>RDN group vs control group.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah32608-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Individual changes in daytime ABPM, by tertile, for abdominal aortic calcification in the RDN group and in the control group, after 6&#x000a0;months of follow&#x02010;up (A: tertile 1; B: tertiles 2 and 3). AAC indicates abdominal aortic calcifications; ABPM, ambulatory blood pressure monitoring; RDN, renal denervation.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-6-e007062-g003"/></fig><table-wrap id="jah32608-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>ADBP at Randomization and After 6&#x02010;Mo Follow&#x02010;up, by Tertile for AAC Volume</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">RDN Group</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Control Group</th><th align="left" rowspan="2" valign="top" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI) Between the 2 Groups at 6&#x000a0;Mo<xref ref-type="fn" rid="jah32608-note-0012">a</xref>
</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Randomization (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;Mo (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">Randomization (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;Mo (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1">Tertile 1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ADBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">(n=13)</td><td align="left" rowspan="1" colspan="1">(n=13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n=17)</td><td align="left" rowspan="1" colspan="1">(n=17)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Daytime</td><td align="left" rowspan="1" colspan="1">99.8&#x000b1;14.7</td><td align="left" rowspan="1" colspan="1">86.7&#x000b1;11.9</td><td align="left" rowspan="1" colspan="1">&#x02212;11.3 (&#x02212;17.3 to &#x02212;5.4)</td><td align="left" rowspan="1" colspan="1">92.8&#x000b1;10.0</td><td align="left" rowspan="1" colspan="1">88.8&#x000b1;12.3</td><td align="left" rowspan="1" colspan="1">&#x02212;5.3 (&#x02212;10.4 to &#x02212;0.1)</td><td align="left" rowspan="1" colspan="1">&#x02212;6.1 (&#x02212;14.1 to 2.0)</td><td align="left" rowspan="1" colspan="1">0.1325</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Nighttime</td><td align="left" rowspan="1" colspan="1">89.6&#x000b1;14.3</td><td align="left" rowspan="1" colspan="1">78.0&#x000b1;11.7</td><td align="left" rowspan="1" colspan="1">&#x02212;8.6 (&#x02212;14.7 to &#x02212;2.4)</td><td align="left" rowspan="1" colspan="1">77.5&#x000b1;7.2</td><td align="left" rowspan="1" colspan="1">73.1&#x000b1;11.3</td><td align="left" rowspan="1" colspan="1">&#x02212;6.7 (&#x02212;12.0 to &#x02212;1.4)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.8 (&#x02212;10.5 to 6.9)</td><td align="left" rowspan="1" colspan="1">0.6708</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">24&#x02010;h</td><td align="left" rowspan="1" colspan="1">97.4&#x000b1;14.6</td><td align="left" rowspan="1" colspan="1">84.5&#x000b1;11.6</td><td align="left" rowspan="1" colspan="1">&#x02212;10.9 (&#x02212;16.6 to &#x02212;5.2)</td><td align="left" rowspan="1" colspan="1">89.2&#x000b1;9.1</td><td align="left" rowspan="1" colspan="1">84.9&#x000b1;11.6</td><td align="left" rowspan="1" colspan="1">&#x02212;5.8 (&#x02212;10.8 to &#x02212;0.9)</td><td align="left" rowspan="1" colspan="1">&#x02212;5.1 (&#x02212;12.8 to 2.7)</td><td align="left" rowspan="1" colspan="1">0.1942</td></tr><tr><td align="left" colspan="9" rowspan="1">Tertiles 2 and 3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ADBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">(n=29)</td><td align="left" rowspan="1" colspan="1">(n=29)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n=31)</td><td align="left" rowspan="1" colspan="1">(n=31)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Daytime</td><td align="left" rowspan="1" colspan="1">90.6&#x000b1;15.3</td><td align="left" rowspan="1" colspan="1">82.2&#x000b1;14.7</td><td align="left" rowspan="1" colspan="1">&#x02212;8.5 (&#x02212;11.7 to &#x02212;5.3)</td><td align="left" rowspan="1" colspan="1">92.0&#x000b1;11.8</td><td align="left" rowspan="1" colspan="1">83.4&#x000b1;13.8</td><td align="left" rowspan="1" colspan="1">&#x02212;8.5 (&#x02212;11.7 to &#x02212;5.4)</td><td align="left" rowspan="1" colspan="1">0.0 (&#x02212;4.5 to 4.5)</td><td align="left" rowspan="1" colspan="1">0.9885</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Nighttime</td><td align="left" rowspan="1" colspan="1">80.7&#x000b1;16.8</td><td align="left" rowspan="1" colspan="1">72.9&#x000b1;13.7</td><td align="left" rowspan="1" colspan="1">&#x02212;7.7 (&#x02212;10.5 to &#x02212;4.9)</td><td align="left" rowspan="1" colspan="1">80.5&#x000b1;12.5</td><td align="left" rowspan="1" colspan="1">75.4&#x000b1;12.3</td><td align="left" rowspan="1" colspan="1">&#x02212;5.1 (&#x02212;7.8 to &#x02212;2.4)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.6 (&#x02212;6.5 to 1.3)</td><td align="left" rowspan="1" colspan="1">0.1811</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">24&#x02010;h</td><td align="left" rowspan="1" colspan="1">87.9&#x000b1;15.5</td><td align="left" rowspan="1" colspan="1">79.3&#x000b1;13.7</td><td align="left" rowspan="1" colspan="1">&#x02212;8.7 (&#x02212;11.4 to &#x02212;5.9)</td><td align="left" rowspan="1" colspan="1">88.9&#x000b1;11.9</td><td align="left" rowspan="1" colspan="1">81.0&#x000b1;12.6</td><td align="left" rowspan="1" colspan="1">&#x02212;7.7 (&#x02212;10.4 to &#x02212;5.1)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.9 (&#x02212;4.7 to 2.9)</td><td align="left" rowspan="1" colspan="1">0.6346</td></tr></tbody></table><table-wrap-foot><fn id="jah32608-note-0011"><p>AAC indicates abdominal aortic calcifications; ADBP, ambulatory diastolic blood pressure; CI, confidence interval; RDN, renal denervation.</p></fn><fn id="jah32608-note-0012"><label>a</label><p>RDN group vs control group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="jah32608-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Ambulatory Heart Rate at Randomization and After 6&#x02010;Mo Follow&#x02010;up by Tertile for AAC Volume in the RDN and Control Groups</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">RDN</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Control Group</th><th align="left" rowspan="2" valign="top" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI) Between the 2 Groups at 6&#x000a0;Mo<xref ref-type="fn" rid="jah32608-note-0014">a</xref>
</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Randomization (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;Mo (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">Randomization (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;Mo (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1">Tertile 1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HR, beats/min</td><td align="left" rowspan="1" colspan="1">(n=13)</td><td align="left" rowspan="1" colspan="1">(n=13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n=17)</td><td align="left" rowspan="1" colspan="1">(n=17)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Daytime</td><td align="left" rowspan="1" colspan="1">79.2&#x000b1;10.7</td><td align="left" rowspan="1" colspan="1">74.5&#x000b1;9.8</td><td align="left" rowspan="1" colspan="1">&#x02212;5.4 (&#x02212;9.9 to &#x02212;0.9)</td><td align="left" rowspan="1" colspan="1">82.0&#x000b1;8.6</td><td align="left" rowspan="1" colspan="1">72.2&#x000b1;8.9</td><td align="left" rowspan="1" colspan="1">&#x02212;9.3 (&#x02212;13.2 to &#x02212;5.3)</td><td align="left" rowspan="1" colspan="1">3.8 (&#x02212;2.2 to 9.9)</td><td align="left" rowspan="1" colspan="1">0.2024</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Nighttime</td><td align="left" rowspan="1" colspan="1">68.8&#x000b1;7.7</td><td align="left" rowspan="1" colspan="1">67.2&#x000b1;8.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1.1 (&#x02212;4.6 to 2.4)</td><td align="left" rowspan="1" colspan="1">66.8&#x000b1;7.8</td><td align="left" rowspan="1" colspan="1">62.6&#x000b1;6.6</td><td align="left" rowspan="1" colspan="1">&#x02212;4.6 (&#x02212;7.7 to &#x02212;1.6)</td><td align="left" rowspan="1" colspan="1">3.5 (&#x02212;1.1 to 8.2)</td><td align="left" rowspan="1" colspan="1">0.1288</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">24&#x02010;h</td><td align="left" rowspan="1" colspan="1">76.8&#x000b1;10.1</td><td align="left" rowspan="1" colspan="1">72.5&#x000b1;9.2</td><td align="left" rowspan="1" colspan="1">&#x02212;4.6 (&#x02212;8.6 to &#x02212;0.7)</td><td align="left" rowspan="1" colspan="1">78.4&#x000b1;7.8</td><td align="left" rowspan="1" colspan="1">69.6&#x000b1;7.7</td><td align="left" rowspan="1" colspan="1">&#x02212;8.4 (&#x02212;11.9 to &#x02212;5.0)</td><td align="left" rowspan="1" colspan="1">3.8 (&#x02212;1.4 to 9.0)</td><td align="left" rowspan="1" colspan="1">0.1460</td></tr><tr><td align="left" colspan="9" rowspan="1">Tertiles 2 and 3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HR, beats/min</td><td align="left" rowspan="1" colspan="1">(n=29)</td><td align="left" rowspan="1" colspan="1">(n=29)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n=31)</td><td align="left" rowspan="1" colspan="1">(n=31)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Daytime</td><td align="left" rowspan="1" colspan="1">74.7&#x000b1;11.7</td><td align="left" rowspan="1" colspan="1">66.5&#x000b1;10.4</td><td align="left" rowspan="1" colspan="1">&#x02212;8.7 (&#x02212;12.6 to &#x02212;4.8)</td><td align="left" rowspan="1" colspan="1">77.2&#x000b1;9.7</td><td align="left" rowspan="1" colspan="1">68.8&#x000b1;13.8</td><td align="left" rowspan="1" colspan="1">&#x02212;7.9 (&#x02212;11.7 to &#x02212;4.1)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.8 (&#x02212;6.2 to 4.7)</td><td align="left" rowspan="1" colspan="1">0.7770</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Nighttime</td><td align="left" rowspan="1" colspan="1">68.0&#x000b1;10.6</td><td align="left" rowspan="1" colspan="1">61.6&#x000b1;10.2</td><td align="left" rowspan="1" colspan="1">&#x02212;6.3 (&#x02212;9.6 to &#x02212;3.0)</td><td align="left" rowspan="1" colspan="1">66.9&#x000b1;8.0</td><td align="left" rowspan="1" colspan="1">62.5&#x000b1;11.9</td><td align="left" rowspan="1" colspan="1">&#x02212;4.5 (&#x02212;7.7 to &#x02212;1.3)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.8 (&#x02212;6.4 to 2.8)</td><td align="left" rowspan="1" colspan="1">0.4402</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">24&#x02010;h</td><td align="left" rowspan="1" colspan="1">72.9&#x000b1;11.4</td><td align="left" rowspan="1" colspan="1">65.1&#x000b1;10.1</td><td align="left" rowspan="1" colspan="1">&#x02212;8.1 (&#x02212;11.7 to &#x02212;4.5)</td><td align="left" rowspan="1" colspan="1">74.5&#x000b1;9.2</td><td align="left" rowspan="1" colspan="1">67.0&#x000b1;12.8</td><td align="left" rowspan="1" colspan="1">&#x02212;7.2 (&#x02212;10.7 to &#x02212;3.7)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.9 (&#x02212;5.9 to 4.1)</td><td align="left" rowspan="1" colspan="1">0.7318</td></tr></tbody></table><table-wrap-foot><fn id="jah32608-note-0013"><p>AAC indicates abdominal aortic calcifications; CI, confidence interval; HR, heart rate; RDN, renal denervation.</p></fn><fn id="jah32608-note-0014"><label>a</label><p>RDN group vs control group.</p></fn></table-wrap-foot></table-wrap><p>The number of antihypertensive drugs prescribed at 6&#x000a0;months did not differ significantly between the RDN and control groups for any of the AAC volume tertiles (Figure&#x000a0;<xref rid="jah32608-fig-0004" ref-type="fig">4</xref>). The proportion of patients with full adherence to SSAHT at 6&#x000a0;months did not differ significantly between the RDN and control groups for any AAC volume tertile (Figure&#x000a0;<xref rid="jah32608-fig-0004" ref-type="fig">4</xref>). The total number of ablations during the RDN procedure did not differ between tertiles for AAC volume (tertiles 2 and 3: 11.0 [10.0&#x02013;12.0]; tertile 1: 11.0 [10.0&#x02013;13.0]; <italic>P</italic>=0.8371).</p><fig fig-type="Figure" xml:lang="en" id="jah32608-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Baseline&#x02010;adjusted changes in daytime ambulatory systolic blood pressure (A and B), number of antihypertensive treatments prescribed (C and D) and percentage of fully adherent patients (E and F) in the renal denervation (red) and control (blue) groups by tertile (tertile 1 vs tertiles 2 and 3 for abdominal aortic calcification volume).</p></caption><graphic id="nlm-graphic-7" xlink:href="JAH3-6-e007062-g004"/></fig></sec><sec id="jah32608-sec-0019"><title>Relationship Between the BP Response to RDN Plus SSAHT and SSAHT and eGFR Changes, by Tertile for AAC Volume</title><p>Regardless of tertile for AAC volume, we previously reported a similar decrease in eGFR in both the RDN and control groups by about 5&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup> at 6&#x000a0;months follow&#x02010;up.<xref rid="jah32608-bib-0001" ref-type="ref">1</xref>
</p><p>However, the analysis of the renal response to RDN by AAC volume tertile revealed 2 contrasting patterns for the BP response. Indeed, eGFR remained stable in the patients in tertile 1 who underwent RDN but decreased significantly in the other 3 subgroups (Table&#x000a0;<xref rid="jah32608-tbl-0006" ref-type="table-wrap">6</xref>). The baseline&#x02010;adjusted difference in the change in eGFR from baseline to 6&#x000a0;months between the RDN and control groups was +10.5&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup> (95% CI, +2.2 to +18.8; <italic>P</italic>=0.0148) in the patients in tertile 1 and &#x02212;3.8&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup> (95% CI, &#x02212;10.6 to 3; <italic>P</italic>=0.2640) in the patients in combined tertiles 2 and 3 (Table&#x000a0;<xref rid="jah32608-tbl-0006" ref-type="table-wrap">6</xref>).</p><table-wrap id="jah32608-tbl-0006" xml:lang="en" orientation="portrait" position="float"><label>Table 6</label><caption><p>eGFR at Randomization and After 6&#x02010;Mo Follow&#x02010;up by Tertile for AAC Volume in the RDN and Control Groups</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">RDN Group</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Control Group</th><th align="left" rowspan="2" valign="top" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI) Between the 2 Groups at 6&#x000a0;Mo<xref ref-type="fn" rid="jah32608-note-0016">a</xref>
</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Randomization (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;Mo (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI)</th><th align="left" valign="top" rowspan="1" colspan="1">Randomization (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;Mo (Mean&#x000b1;SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Mean Baseline&#x02010;Adjusted Difference (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1">Tertile 1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">eGFR, mL/min</td><td align="left" rowspan="1" colspan="1">(n=12)</td><td align="left" rowspan="1" colspan="1">(n=13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n=17)</td><td align="left" rowspan="1" colspan="1">(n=17)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">99.1&#x000b1;31.9</td><td align="left" rowspan="1" colspan="1">100.0&#x000b1;28.5</td><td align="left" rowspan="1" colspan="1">2.5 (&#x02212;3.8 to 8.8)</td><td align="left" rowspan="1" colspan="1">97.6&#x000b1;22.4</td><td align="left" rowspan="1" colspan="1">89.6&#x000b1;20.9</td><td align="left" rowspan="1" colspan="1">&#x02212;8.0 (&#x02212;13.4 to &#x02212;2.7)</td><td align="left" rowspan="1" colspan="1">10.5 (2.2&#x02013;18.8)</td><td align="left" rowspan="1" colspan="1">0.0148</td></tr><tr><td align="left" colspan="9" rowspan="1">Tertiles 2 and 3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">eGFR, mL/min</td><td align="left" rowspan="1" colspan="1">(n=29)</td><td align="left" rowspan="1" colspan="1">(n=27)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n=31)</td><td align="left" rowspan="1" colspan="1">(n=31)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">86.1&#x000b1;21.3</td><td align="left" rowspan="1" colspan="1">76.8&#x000b1;21.9</td><td align="left" rowspan="1" colspan="1">&#x02212;7.5 (&#x02212;12.5 to &#x02212;2.6)</td><td align="left" rowspan="1" colspan="1">85.5&#x000b1;24.3</td><td align="left" rowspan="1" colspan="1">81.7&#x000b1;23.5</td><td align="left" rowspan="1" colspan="1">&#x02212;3.7 (&#x02212;8.3 to 0.9)</td><td align="left" rowspan="1" colspan="1">&#x02212;3.8 (&#x02212;10.6 to 3.0)</td><td align="left" rowspan="1" colspan="1">0.2640</td></tr></tbody></table><table-wrap-foot><fn id="jah32608-note-0015"><p>AAC indicates abdominal aortic calcifications; CI, confidence interval; eGFR, estimated glomerular filtration rate; RDN, renal denervation.</p></fn><fn id="jah32608-note-0016"><label>a</label><p>RDN group vs control group.</p></fn></table-wrap-foot></table-wrap><p>We plotted eGFR changes in response to the BP changes by AAC volume tertile for the RDN and control groups (Figure&#x000a0;<xref rid="jah32608-fig-0005" ref-type="fig">5</xref>). The RDN&#x02010;induced decrease in daytime ambulatory SBP, which was greatest in the patients of tertile 1, was associated with no change in eGFR at 6&#x000a0;months (Figure&#x000a0;<xref rid="jah32608-fig-0005" ref-type="fig">5</xref>). Conversely, the decrease in daytime ambulatory SBP was associated with a decrease in eGFR in the other subgroups (Figure&#x000a0;<xref rid="jah32608-fig-0005" ref-type="fig">5</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah32608-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Relationship between the changes from baseline to 6&#x000a0;months in mean baseline&#x02010;adjusted eGFR and daytime ambulatory SBP in the 4 subgroups of patients. Red plot: patients of tertile 1 for AAC volume treated with RDN plus SSAHT; green plot: patients of tertiles 2 and 3 for AAC volume treated with RDN plus SSAHT; blue plot: patients of tertile 1 for AAC volume treated with SSAHT alone; orange plot: patients of tertiles 2 and 3 for AAC volume treated with SSAHT alone. The data shown are mean&#x000b1;SD. AAC indicates abdominal aortic calcifications; eGFR, estimated glomerular filtration rate; RDN, renal denervation; SBP, systolic blood pressure; SSAHT, standardized stepped&#x02010;care antihypertensive treatment.</p></caption><graphic id="nlm-graphic-9" xlink:href="JAH3-6-e007062-g005"/></fig><p>There was no significant change in urinary albumin:creatinine ratio during follow&#x02010;up, and the difference between groups and within each stratum of AAC volume was not significant (not shown).</p></sec></sec><sec id="jah32608-sec-0020"><title>Discussion</title><p>This post hoc exploratory analysis of the DENERHTN trial investigated the impact of AAC burden, as assessed by pre&#x02010;RDN abdominal CT scans, on 6&#x02010;month ambulatory BP and eGFR responses to RDN and SSAHT in patients with resistant hypertension. Our results show that the combination of RDN and SSAHT reduced 6&#x02010;month daytime ambulatory SBP significantly more strongly (by &#x02248;10&#x000a0;mm&#x000a0;Hg) than the same SSAHT alone in the patients with the lowest AAC volumes (tertile 1, range: 0&#x02013;0.122&#x000a0;cm<sup>3</sup>). In contrast, the difference in the change in daytime ambulatory SBP between the RDN and control groups was much smaller (&#x02248;2&#x02013;3&#x000a0;mm&#x000a0;Hg) and not significant in patients with greater atherosclerotic burden (tertiles 2 and 3 for AAC volume). The change in eGFR from baseline to 6&#x000a0;months in response to RDN was also influenced by AAC burden. Indeed, eGFR remained stable in the patients in tertile 1 who underwent RDN (+2.5&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>) but decreased in the other 3 subgroups (by &#x02248;4&#x02013;8&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>). These preliminary results suggest that measurement of AAC burden on abdominal CT scans without contrast staining before RDN may be a new predictor of short&#x02010;term BP and renal responses to RDN.</p><p>We report the first quantification of AAC burden in a population of patients with resistant hypertension selected for the DENERHTN trial. AAC has been studied extensively in other clinical settings, including patients with high cardiovascular risk or chronic kidney disease,<xref rid="jah32608-bib-0015" ref-type="ref">15</xref>, <xref rid="jah32608-bib-0016" ref-type="ref">16</xref> and the extent of these calcifications has been associated with a poor cardiovascular and renal prognosis.<xref rid="jah32608-bib-0014" ref-type="ref">14</xref>, <xref rid="jah32608-bib-0015" ref-type="ref">15</xref> The radiological methods used in these studies included qualitative or semiquantitative measurements of AAC burden on lateral lumbar x&#x02010;rays, aortic angiograms, and CT scans.<xref rid="jah32608-bib-0017" ref-type="ref">17</xref>, <xref rid="jah32608-bib-0018" ref-type="ref">18</xref>, <xref rid="jah32608-bib-0019" ref-type="ref">19</xref> In the DENERHTN study, we performed an abdominal CT scan (or MRI in a few cases, n=7) for patients with resistant hypertension before randomization to exclude secondary hypertension and to assess the suitability of the renal artery anatomy for RDN. All CT scans were sent to the imaging core laboratory, where the volume of AAC was measured on noncontrast images, with semiautomatic software, with good within&#x02010; and between&#x02010;observer reproducibility, as reported in other studies.<xref rid="jah32608-bib-0007" ref-type="ref">7</xref>, <xref rid="jah32608-bib-0019" ref-type="ref">19</xref> About 80% of our patients with resistant hypertension confirmed by ambulatory BP monitoring had visible AAC. Median AAC volume was 0.438&#x000a0;cm<sup>3</sup>, but there were considerable differences between patients (0&#x02013;11.100&#x000a0;cm<sup>3</sup>). This prevalence of AAC is higher than that reported in a large, independently living, middle&#x02010;aged, and mostly asymptomatic US population of 6456 participants (28% with hypertension) in whom the prevalence of AAC was 54.3% on noncontrast CT imaging.<xref rid="jah32608-bib-0020" ref-type="ref">20</xref> Our results also expand those of a small study reporting AAC volume on CT scan to be greater in 15 patients with treatment&#x02010;resistant hypertension or with ISH than in normotensive participants.<xref rid="jah32608-bib-0006" ref-type="ref">6</xref>, <xref rid="jah32608-bib-0007" ref-type="ref">7</xref> The baseline clinical and biological characteristics of our patients with resistant hypertension and the highest AAC burden were consistent with previous reports from normotensive and hypertensive cohorts.<xref rid="jah32608-bib-0007" ref-type="ref">7</xref> These patients tended to be older, with a history of smoking, type 2 diabetes mellitus, hyperlipidemia, obstructive sleep apnea, and prior cardiovascular events, and they were more likely to have a lower eGFR. As expected, higher AAC volume was also associated with greater arterial stiffness, as shown by the higher carotid&#x02013;femoral PWV and ambulatory pulse pressure and, consequently, a higher proportion of patients with ISH in tertiles 2 and 3 than in tertile 1 at baseline. The pathophysiological mechanisms underlying the development of arterial calcifications involving the abdominal aorta are complex and multifactorial.<xref rid="jah32608-bib-0016" ref-type="ref">16</xref>
</p><p>The principal finding of our post hoc analysis was that AAC burden influences both the systemic and renal hemodynamic responses to RDN at 6&#x000a0;months, regardless of the number of antihypertensive drugs used or adherence to the SSAHT, which were similar for all AAC tertiles. Indeed, the largest significant difference in the change in daytime ambulatory SBP in favor of RDN (&#x02212;10&#x000a0;mm&#x000a0;Hg) was observed in the patients in tertile 1, those with the lowest atherosclerotic burden. Conversely, RDN was less effective at lowering BP relative to the control group (&#x02212;2.5&#x000a0;mm&#x000a0;Hg) in patients with the highest AAC burden (tertiles 2 and 3). The apparently greater ambulatory SBP response to the SSAHT alone in the patients in combined tertiles 2 and 3 than in those of tertile 1 can be explained, in part, by the higher ambulatory SBP of these patients at baseline (see Table&#x000a0;<xref rid="jah32608-tbl-0003" ref-type="table-wrap">3</xref>). The weaker BP response to RDN in the patients with the greatest AAC burden is consistent with the lower office and ambulatory BP reported in patients with ISH than in those with both systolic and diastolic hypertension.<xref rid="jah32608-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32608-bib-0010" ref-type="ref">10</xref> However, despite the higher frequency of ISH in the patients in tertiles 2 and 3 for AAC volume than in those in tertile 1, these 2 conditions were not strictly superimposable. Indeed, 20% of patients with ISH had no visible AAC, and &#x02248;70% of the patients with the highest AAC burden (tertiles 2 and 3) had combined systolic and diastolic hypertension without ISH; only 30% of the patients had both conditions (ISH and a high AAC burden). The presence of AAC is a BP&#x02010;independent marker of aortic stiffness and thus of vascular aging<xref rid="jah32608-bib-0007" ref-type="ref">7</xref> that also takes into account the overall extent of atherosclerosis burden and is associated with a risk of poor cardiovascular outcome.<xref rid="jah32608-bib-0011" ref-type="ref">11</xref> In our study, high AAC volume was an integrative biomarker of the multiple factors associated with lower efficacy of RDN for lowering BP. These factors included older age,<xref rid="jah32608-bib-0021" ref-type="ref">21</xref> ISH,<xref rid="jah32608-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32608-bib-0010" ref-type="ref">10</xref> lower GFR,<xref rid="jah32608-bib-0021" ref-type="ref">21</xref> and vascular stiffness.<xref rid="jah32608-bib-0022" ref-type="ref">22</xref> Conversely, the larger BP response to RDN than to SSAHT in patients with little or no AAC, and thus less vascular remodeling, may reflect the predominant contribution of the renal sympathetic drive to the pathophysiology of resistant hypertension in these patients, who tend to be younger and to have fewer comorbid conditions, consistent with the results of renal norepinephrine spillover experiments.<xref rid="jah32608-bib-0023" ref-type="ref">23</xref>
</p><p>The relationship between daytime ambulatory SBP decrease and the change in eGFR at 6&#x000a0;months also differed between the AAC volume tertile subgroups. Indeed, eGFR was found to remain stable 6&#x000a0;months after RDN in the patients in tertile 1, who displayed the largest decrease in BP. Conversely, eGFR decreased in parallel with BP in the other 3 subgroups. A small decrease in eGFR is usually observed in the context of better BP control in patients with hypertension, due to intraglomerular pressure reduction.<xref rid="jah32608-bib-0024" ref-type="ref">24</xref> In cases of long&#x02010;standing hypertension, microvascular disease is observed in the kidney, characterized by a blunted vasoconstrictive or vasodilatory capacity of the preglomerular afferent arterioles in response to changes in renal perfusion pressure; therefore, any change in systemic and renal pressure is associated with a proportional change in GFR.<xref rid="jah32608-bib-0008" ref-type="ref">8</xref> This phenomenon is exacerbated in the presence of AAC and aortic stiffening, which induce the transmission of abnormally high pulsatile stresses in renal microvessels.<xref rid="jah32608-bib-0025" ref-type="ref">25</xref>, <xref rid="jah32608-bib-0026" ref-type="ref">26</xref> In this pathophysiological context, the maintenance of eGFR despite a large decrease in BP suggests that the addition of RDN to SSAHT including a renin&#x02013;angiotensin system blocker and a calcium channel blocker (acting on postglomerular and both pre&#x02010;and postglomerular resistances,<xref rid="jah32608-bib-0027" ref-type="ref">27</xref> respectively) may have induced specific and subtle renal hemodynamic changes detectable only in the patients with the lowest AAC burden, as expected from experimental models.<xref rid="jah32608-bib-0028" ref-type="ref">28</xref>, <xref rid="jah32608-bib-0029" ref-type="ref">29</xref> A small cohort study reported an increase in renal artery mean flow 6&#x000a0;months after RDN, as assessed by 3&#x02010;dimensional magnetic resonance angiography.<xref rid="jah32608-bib-0030" ref-type="ref">30</xref> In addition, renal vascular resistance has been shown to decrease 3 to 6&#x000a0;months after RDN in patients with resistant hypertension,<xref rid="jah32608-bib-0031" ref-type="ref">31</xref>, <xref rid="jah32608-bib-0032" ref-type="ref">32</xref> with no significant increase in renal perfusion detectable on MRI<xref rid="jah32608-bib-0033" ref-type="ref">33</xref> or improvement in renal oxygenation, as determined by blood oxygen level&#x02013;dependent MRI.<xref rid="jah32608-bib-0032" ref-type="ref">32</xref> However, in a small cohort study of 27 patients with stage 3 or 4 chronic kidney disease, the annual decrease in eGFR was slightly smaller after than before RDN, and this effect was accompanied by a significant decrease in office BP.<xref rid="jah32608-bib-0034" ref-type="ref">34</xref> These mixed renal effects of RDN may be caused by (1) incomplete RDN, (2) the absence of a control group, or (3) the heterogeneity of the patients, because none of the studies checked for an influence of AAC burden, even though they included patients with chronic kidney disease.</p><p>Finally, our results suggest that changes in the viscoelastic properties of the aorta, and likely of large arteries in other territories, associated with increasing AAC volume are probably contributing factors influencing variability in the BP and renal responses to RDN. The other factors identified include high BP at baseline, older age, being white, preserved renal function, previous use of spironolactone, adherence to antihypertensive treatment, and the presence of ISH and of accessory renal arteries.<xref rid="jah32608-bib-0001" ref-type="ref">1</xref>, <xref rid="jah32608-bib-0002" ref-type="ref">2</xref>, <xref rid="jah32608-bib-0009" ref-type="ref">9</xref>, <xref rid="jah32608-bib-0010" ref-type="ref">10</xref>, <xref rid="jah32608-bib-0021" ref-type="ref">21</xref>, <xref rid="jah32608-bib-0035" ref-type="ref">35</xref>, <xref rid="jah32608-bib-0036" ref-type="ref">36</xref> The identification of predictors of BP and renal responses to RDN, for use before and during the RDN procedure, remains crucial.<xref rid="jah32608-bib-0005" ref-type="ref">5</xref>
</p><sec id="jah32608-sec-0021"><title>Study Limitations</title><p>The limitations of the DENERHTN trial have been discussed elsewhere.<xref rid="jah32608-bib-0001" ref-type="ref">1</xref> The limitations of this post hoc analysis include its exploratory nature, allowing only hypothesis&#x02010;generating conclusions to be drawn. Other limitations include the following: (1) The study was not designed to explore the underlying pathophysiologic mechanisms of the differential hemodynamic and renal effects of RDN according to atherosclerotic burden, and thus GFR and renal plasma flow were not measured with exogenous markers; (2) none of the patients had baseline eGFR values &#x0003c;40&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup>; (3) we cannot fully exclude a &#x0201c;Hawthorne&#x0201d; effect, because there was no sham group.<xref rid="jah32608-bib-0037" ref-type="ref">37</xref> However, the differential BP and renal responses to RDN 6&#x000a0;months after baseline, according to AAC volume tertile, were not confounded by differences in the number of renal ablations in the RDN groups, the number of antihypertensive drugs prescribed at 6&#x000a0;months in any of the subgroups, or adherence to SSAHT at 6&#x000a0;months, as assessed by drug detection in the urine or plasma in any of the subgroups. However, the technical success of renal nerve ablation with the Symplicity catheter might vary, resulting in variable degrees of renal nerve damage that can be an independent contributor to the BP response. The large differences in BP and renal responses to RDN between tertiles for AAC volume suggest (1) that AAC burden influences the BP and renal responses to RDN and (2) that their measurements on pre&#x02010;RDN noncontrast abdominal CT scan should be included in ongoing clinical trials. However, our thresholds of AAC volume are not directly applicable to other populations of patients because they rely on the CT scan, the image characteristics, and the software used to detect and measure AAC. Consequently, each center should determine its thresholds of AAC volume.</p></sec></sec><sec id="jah32608-sec-0022"><title>Conclusion</title><p>This post hoc exploratory analysis of the DENERHTN trial taking into account the AAC burden, as assessed by a semiautomatic method on pre&#x02010;RDN noncontrast abdominal CT scans, suggested differential patterns of systemic and renal hemodynamic response to RDN in the short term.</p><p>We found that the additional reduction in daytime ambulatory SBP achieved by adding RDN to SSAHT (1) was largest (&#x02248;10&#x000a0;mm&#x000a0;Hg) and statistically significant in patients with the lowest atherosclerotic burden and (2) was not associated with a decrease in eGFR. Further studies will be required to confirm these preliminary results and to determine whether the short&#x02010;term renal hemodynamic effects of RDN in patients with a low atherosclerotic burden have a beneficial effect in the long term. A loss in eGFR of 9.3&#x000a0;mL/min per 1.73&#x000a0;m<sup>2</sup> at 3&#x000a0;years was observed in the SYMPLICITY HTN&#x02010;1 cohort study, but this study did not take into account the AAC burden.<xref rid="jah32608-bib-0038" ref-type="ref">38</xref>
</p><p>Because RDN appears to be associated with a limited risk of adverse events,<xref rid="jah32608-bib-0001" ref-type="ref">1</xref>, <xref rid="jah32608-bib-0035" ref-type="ref">35</xref> randomized sham&#x02010;controlled trials are currently under way to assess the efficacy of RDN for lowering ambulatory BP and its safety, with various radiofrequency&#x02010; or ultrasound&#x02010;based denervation catheters or externally delivered ultrasound technologies; the preliminary results of these studies are expected in 2018.<xref rid="jah32608-bib-0005" ref-type="ref">5</xref> These trials include patients with resistant hypertension treated with standardized antihypertensive treatment regimens and with strict monitoring of adherence to treatment. However, they also include patients with milder forms of hypertension whose treatment with antihypertensive drugs could be stopped for a limited period.<xref rid="jah32608-bib-0039" ref-type="ref">39</xref> Our results suggest that the evaluation of AAC burden on pre&#x02010;RDN noncontrast CT scans should be part of the data collected during the trials to analyze the BP and eGFR results taking into account the AAC burden.</p></sec><sec id="jah32608-sec-0023"><title>Appendix</title><sec id="jah32608-sec-0024"><title>List of the DENERHTN Investigators</title><p>The following investigators (with the number of patients enrolled and randomized at each center given in parentheses) and committees participated in the DENERHTN trial: H&#x000f4;pital Europ&#x000e9;en Georges Pompidou, Paris (31/28)&#x02014;L. Amar, G. Bobrie, A. Lorthioir, M. Monge, J.&#x02010;Y. Pagny, P. F. Plouin, M. Sapoval; H&#x000f4;pital Cardiologique, Lille (20/15)&#x02014;G. Claisse, P. Delsart, M. Midulla, C. Mounier&#x02010;Vehier; H&#x000f4;pital de la Croix Rousse and H&#x000f4;pital Edouard Herriot, Lyon (14/13)&#x02014;P. Y. Courand, R. Dauphin, J. P. Fauvel, P. Lantelme, O. Rouvi&#x000e8;re; H&#x000f4;pital Saint Andr&#x000e9; and H&#x000f4;pital Pellegrin, Bordeaux (14/13)&#x02014;A. Cremer, P. Gosse, N. Grenier, Y. Lebras, H. Trillaud; H&#x000f4;pital Arthur Gardiner, Dinard and CHU Rennes (12/12)&#x02014;T. Denolle, C. Dourmap&#x02010;Collas, J. F. Heautot, A. Larralde, F. Paillard; H&#x000f4;pital de la Piti&#x000e9; Salp&#x000e9;tri&#x000e8;re, Paris (6/5)&#x02014;P. Cluzel, X. Girerd, D. Rosenbaum; H&#x000f4;pital Bretonneau, Tours (5/4)&#x02014;D. Alison, J. M. Halimi; CHU Nancy&#x02010;Brabois, Nancy (4/1)&#x02014;M. Claudon, B. Popovic, P. Rossignol, F. Zannad; CHU de Grenoble, Grenoble (3/3)&#x02014;J. P. Baguet, O. Ormezzano, F. Thony; CHU de la Timone, Marseille (3/3)&#x02014;J. M. Bartoli, B. Va&#x000ef;sse; H&#x000f4;pital la Mil&#x000e9;trie, Poitiers (3/3)&#x02014;J. Drouineau, D. Herpin, P. Sosner, J. P. Tasu, S. Velasco; H&#x000f4;pital Lapeyronie and H&#x000f4;pital Arnaud de Villeneuve, Montpellier (2/2)&#x02014;J. Ribstein, H. Vernhet&#x02010;Kovacsik; CHU Rangueil, Toulouse (2/2)&#x02014;B. Bouhanick, B. Chamontin, H. Rousseau; H&#x000f4;pital Avicenne, Bobigny (1/1)&#x02014;S. Le Jeune, M. Lopez&#x02010;Sublet, J. J. Mourad; H&#x000f4;pital Pasteur, Nice (1/1)&#x02014;L. Bellmann, V. Esnault, E. Ferrari; Scientific Committee&#x02014;M. Azizi (Chair), M. Sapoval (Co&#x02010;Chair), G. Bobrie, G. Chatellier, P. F. Plouin, F. Zannad, J. M. Halimi, J. P. Baguet, H. Vernhet&#x02010;Kovacsik, I. Durand&#x02010;Zaleski; Data Safety Committee&#x02014;J. P. Beregi (Chair), M. Li&#x000e8;vre, A. Persu.</p></sec></sec><sec id="jah32608-sec-0026"><title>Sources of Funding</title><p>This trial was sponsored by the Assistance Publique&#x02010;H&#x000f4;pitaux de Paris and was funded by a grant from the French Ministry of Health (Soutien aux Technologies Innovantes et Co&#x000fb;teuses 2011, IC110175).</p></sec><sec id="jah32608-sec-0027"><title>Disclosures</title><p>Bobrie received grant from the French Health Minister. Delsart has no conflict of interest. Claire Mounier&#x02010;V&#x000e9;hier has received personal fees from Bayer Pharma and Non&#x02010;financial support from Bayer Pharma, Novartis, MSD, Daichi Sankyo, Astra Z&#x000e9;n&#x000e9;ca, Leo Pharma and Novonordisk. Girerd received personal fees form Bouchara Recodati, Sanofi, Merck and Sothema. Rossignol received personal fees from Novartis, Relypsa, Astra&#x02010;Zeneca, Stealth Peptides, CVRx, Fresenius, Vifor Fresenius Medical Care Renal Pharma, CTMA and is cofounder of CardioRenal. Zannad received personal fees from Janssen, Bayer, Pfizer, Novartis, Boston Scientific, Resmed, Amgen, CVRx, Quantum Genomics, Takeda, General Electric, Boehringer, Relypsa, Zs Pharma, Astra Zeneca, Roche Diagnostics and was founder of cardiorenal and CVCT. Ribstein received grants from Otsuka and consulting fees from Bayer, Bristol&#x02010;Myers&#x02010;Squibb, Menarini, Novartis, Sanofi&#x02010;Aventis and Servier. Azizi has received honoraria for advisory board meetings from Vessix, Boston Scientific Corporation, Cordis, Actelion, has received speakers&#x02019; honoraria from Cordis, CVRx, Servier; was involved as investigator in Symplicity HTN&#x02010;2 (Ardian/Medtronic) and Reduce&#x02010;HTN (Vessix/Boston Scientific Corporation) trials; has received a research grant from Servier, Novartis, Recor, Quantum genomics. The remaining authors have no disclosures to report.</p></sec></body><back><ack id="jah32608-sec-0025"><title>Acknowledgments</title><p>We thank Pascaline Aucouturier, Nicolas Hollebecq, Nathalie Gomes, Laroussi Ben Zrig, and Abderraouf Bensaber from the Clinical Trials Unit of Georges Pompidou European Hospital for organizing the trial, and for data monitoring, collection, and management. We thank all the nursing teams and the DENERHTN investigators for their involvement in patient care.</p></ack><ref-list content-type="cited-references" id="jah32608-bibl-0001"><title>References</title><ref id="jah32608-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah32608-cit-0001">
<string-name>
<surname>Azizi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sapoval</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gosse</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Monge</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bobrie</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Delsart</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Midulla</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mounier&#x02010;Vehier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Courand</surname>
<given-names>PY</given-names>
</string-name>, <string-name>
<surname>Lantelme</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Denolle</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dourmap&#x02010;Collas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Trillaud</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pereira</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Plouin</surname>
<given-names>PF</given-names>
</string-name>, <string-name>
<surname>Chatellier</surname>
<given-names>G</given-names>
</string-name>. <article-title>Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open&#x02010;label, randomised controlled trial</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>385</volume>:<fpage>1957</fpage>&#x02013;<lpage>1965</lpage>.<pub-id pub-id-type="pmid">25631070</pub-id></mixed-citation></ref><ref id="jah32608-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah32608-cit-0002">
<string-name>
<surname>Azizi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pereira</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hamdidouche</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Gosse</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Monge</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bobrie</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Delsart</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mounier&#x02010;Vehier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Courand</surname>
<given-names>PY</given-names>
</string-name>, <string-name>
<surname>Lantelme</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Denolle</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dourmap&#x02010;Collas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Girerd</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Halimi</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Zannad</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ormezzano</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Vaisse</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Herpin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ribstein</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chamontin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mourad</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Plouin</surname>
<given-names>PF</given-names>
</string-name>, <string-name>
<surname>Jullien</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Sapoval</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chatellier</surname>
<given-names>G</given-names>
</string-name>. <article-title>Adherence to antihypertensive treatment and the blood pressure lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) trial</article-title>. <source>Circulation</source>. <year>2016</year>;<volume>134</volume>:<fpage>847</fpage>&#x02013;<lpage>857</lpage>.<pub-id pub-id-type="pmid">27576780</pub-id></mixed-citation></ref><ref id="jah32608-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah32608-cit-0003">
<string-name>
<surname>Gosse</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cremer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pereira</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bobrie</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chatellier</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chamontin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Courand</surname>
<given-names>PY</given-names>
</string-name>, <string-name>
<surname>Delsart</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Denolle</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dourmap</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Girerd</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Halimi</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Herpin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lantelme</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Monge</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mounier&#x02010;Vehier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mourad</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Ormezzano</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Ribstein</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rossignol</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sapoval</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Va&#x000ef;sse</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Zannad</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Azizi</surname>
<given-names>M</given-names>
</string-name>. <article-title>Twenty&#x02010;four&#x02010;hour blood pressure monitoring to predict and assess impact of renal denervation: the DENERHTN Study (Renal Denervation for Hypertension)</article-title>. <source>Hypertension</source>. <year>2017</year>;<volume>69</volume>:<fpage>494</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">28115517</pub-id></mixed-citation></ref><ref id="jah32608-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah32608-cit-0004">
<string-name>
<surname>Persu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kjeldsen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Staessen</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Azizi</surname>
<given-names>M</given-names>
</string-name>. <article-title>Renal denervation for treatment of hypertension: a second start and new challenges</article-title>. <source>Curr Hypertens Rep</source>. <year>2016</year>;<volume>18</volume>:<fpage>6</fpage>.<pub-id pub-id-type="pmid">26739586</pub-id></mixed-citation></ref><ref id="jah32608-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah32608-cit-0005">
<string-name>
<surname>Mahfoud</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>B&#x000f6;hm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Azizi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pathak</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Durand Zaleski</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Ewen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tsioufis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Andersson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Blankestijn</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Burnier</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chatellier</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gafoor</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Grassi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Joner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kjeldsen</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>L&#x000fc;scher</surname>
<given-names>TF</given-names>
</string-name>, <string-name>
<surname>Lobo</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Lotan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Parati</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Redon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ruilope</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sudano</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Ukena</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>van Leeuwen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Volpe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Windecker</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Witkowski</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wijns</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Zeller</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Schmieder</surname>
<given-names>RE</given-names>
</string-name>. <article-title>Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design</article-title>. <source>Eur Heart J</source>. <year>2015</year>;<volume>36</volume>:<fpage>2219</fpage>&#x02013;<lpage>2227</lpage>.<pub-id pub-id-type="pmid">25990344</pub-id></mixed-citation></ref><ref id="jah32608-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah32608-cit-0006">
<string-name>
<surname>Cecelja</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hussain</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Greil</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Botnar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Preston</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Moayyeri</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Spector</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Chowienczyk</surname>
<given-names>P</given-names>
</string-name>. <article-title>Multimodality imaging of subclinical aortic atherosclerosis: relation of aortic stiffness to calcification and plaque in female twins</article-title>. <source>Hypertension</source>. <year>2013</year>;<volume>61</volume>:<fpage>609</fpage>&#x02013;<lpage>614</lpage>.<pub-id pub-id-type="pmid">23339166</pub-id></mixed-citation></ref><ref id="jah32608-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah32608-cit-0007">
<string-name>
<surname>McEniery</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>McDonnell</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>So</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Aitken</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bolton</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Munnery</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hickson</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Yasmin</surname>
<given-names>&#x000a0;</given-names>
</string-name>, <string-name>
<surname>Maki&#x02010;Petaja</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Cockcroft</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Dixon</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Wilkinson</surname>
<given-names>IB</given-names>
</string-name>. <article-title>Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals</article-title>. <source>Hypertension</source>. <year>2009</year>;<volume>53</volume>:<fpage>524</fpage>&#x02013;<lpage>531</lpage>.<pub-id pub-id-type="pmid">19171791</pub-id></mixed-citation></ref><ref id="jah32608-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah32608-cit-0008">
<string-name>
<surname>Mancia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Giannattasio</surname>
<given-names>C</given-names>
</string-name>. <article-title>Diagnostic and therapeutic problems of isolated systolic hypertension</article-title>. <source>J Hypertens</source>. <year>2015</year>;<volume>33</volume>:<fpage>33</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">25426565</pub-id></mixed-citation></ref><ref id="jah32608-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah32608-cit-0009">
<string-name>
<surname>Ewen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ukena</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Linz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kindermann</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Cremers</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Laufs</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Wagenpfeil</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schmieder</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>B&#x000f6;hm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mafhoud</surname>
<given-names>F</given-names>
</string-name>. <article-title>Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension</article-title>. <source>Hypertension</source>. <year>2015</year>;<volume>65</volume>:<fpage>193</fpage>&#x02013;<lpage>199</lpage>.<pub-id pub-id-type="pmid">25331843</pub-id></mixed-citation></ref><ref id="jah32608-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah32608-cit-0010">
<string-name>
<surname>Mahfoud</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bakris</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Esler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ewen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fahy</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kandzari</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kario</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mancia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Weber</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>B&#x000f6;hm</surname>
<given-names>M</given-names>
</string-name>. <article-title>Reduced blood pressure&#x02010;lowering effect of catheter&#x02010;based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN&#x02010;3 and the Global SYMPLICITY Registry</article-title>. <source>Eur Heart J</source>. <year>2017</year>;<volume>38</volume>:<fpage>93</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">28158510</pub-id></mixed-citation></ref><ref id="jah32608-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="jah32608-cit-0011">
<string-name>
<surname>Mory</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ardon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yezzi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Thiran</surname>
<given-names>J</given-names>
</string-name>. <article-title>Non&#x02010;Euclidean image&#x02010;adaptative radial basis functions for 3D interactive segmentation</article-title>. 2009 IEEE 12th Int Conf Comput Vis Kyoto Jpn <year>2009</year>;<fpage>787</fpage>&#x02013;<lpage>794</lpage>.</mixed-citation></ref><ref id="jah32608-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah32608-cit-0012">
<collab collab-type="authors">Reference Values for Arterial Stiffness&#x02019; Collaboration</collab>
. <article-title>Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: &#x0201c;establishing normal and reference values&#x0201d;</article-title>. <source>Eur Heart J</source>. <year>2010</year>;<volume>31</volume>:<fpage>2338</fpage>&#x02013;<lpage>2350</lpage>.<pub-id pub-id-type="pmid">20530030</pub-id></mixed-citation></ref><ref id="jah32608-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah32608-cit-0013">
<string-name>
<surname>Stea</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bozec</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Millasseau</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Khettab</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Boutouyrie</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Laurent</surname>
<given-names>S</given-names>
</string-name>. <article-title>Comparison of the Complior Analyse device with Sphygmocor and Complior SP for pulse wave velocity and central pressure assessment</article-title>. <source>J Hypertens</source>. <year>2014</year>;<volume>32</volume>:<fpage>873</fpage>&#x02013;<lpage>880</lpage>.<pub-id pub-id-type="pmid">24509122</pub-id></mixed-citation></ref><ref id="jah32608-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah32608-cit-0014">
<string-name>
<surname>Levey</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Eckardt</surname>
<given-names>KU</given-names>
</string-name>, <string-name>
<surname>Tsukamoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Levin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Coresh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rossert</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>De Zeeuw</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hostetter</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Lameire</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Eknoyan</surname>
<given-names>G</given-names>
</string-name>. <article-title>Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)</article-title>. <source>Kidney Int</source>. <year>2005</year>;<volume>67</volume>:<fpage>2089</fpage>&#x02013;<lpage>2100</lpage>.<pub-id pub-id-type="pmid">15882252</pub-id></mixed-citation></ref><ref id="jah32608-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah32608-cit-0015">
<string-name>
<surname>Bastos Goncalves</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Vo&#x000fb;te</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hoeks</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chonchol</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Boersma</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Stolker</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Verhagen</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Calcification of the abdominal aorta as an independent predictor of cardiovascular events</article-title>. <source>Heart</source>. <year>2012</year>;<volume>98</volume>:<fpage>988</fpage>&#x02013;<lpage>994</lpage>.<pub-id pub-id-type="pmid">22668866</pub-id></mixed-citation></ref><ref id="jah32608-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah32608-cit-0016">
<string-name>
<surname>London</surname>
<given-names>GM</given-names>
</string-name>. <article-title>Mechanisms of arterial calcifications and consequences for cardiovascular function</article-title>. <source>Kidney Int Suppl</source>. <year>2013</year>;<volume>3</volume>:<fpage>442</fpage>&#x02013;<lpage>445</lpage>.</mixed-citation></ref><ref id="jah32608-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah32608-cit-0017">
<string-name>
<surname>Courand</surname>
<given-names>PY</given-names>
</string-name>, <string-name>
<surname>Milon</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bricca</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Khettab</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lantelme</surname>
<given-names>P</given-names>
</string-name>. <article-title>Diastolic blood pressure, aortic atheroma, and prognosis in hypertension: new insights into a complex association</article-title>. <source>Atherosclerosis</source>. <year>2014</year>;<volume>233</volume>:<fpage>300</fpage>&#x02013;<lpage>306</lpage>.<pub-id pub-id-type="pmid">24495793</pub-id></mixed-citation></ref><ref id="jah32608-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah32608-cit-0018">
<string-name>
<surname>Harbaoui</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Montoy</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Charles</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Boussel</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Liebgott</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Girerd</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Courand</surname>
<given-names>PY</given-names>
</string-name>, <string-name>
<surname>Lantelme</surname>
<given-names>P</given-names>
</string-name>. <article-title>Aorta calcification burden: towards an integrative predictor of cardiac outcome after transcatheter aortic valve implantation</article-title>. <source>Atherosclerosis</source>. <year>2016</year>;<volume>246</volume>:<fpage>161</fpage>&#x02013;<lpage>168</lpage>.<pub-id pub-id-type="pmid">26784328</pub-id></mixed-citation></ref><ref id="jah32608-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah32608-cit-0019">
<string-name>
<surname>Wilson</surname>
<given-names>PWF</given-names>
</string-name>, <string-name>
<surname>Kauppila</surname>
<given-names>LI</given-names>
</string-name>, <string-name>
<surname>O'Donnell</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Kiel</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Hannan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Polak</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Cupples</surname>
<given-names>LA</given-names>
</string-name>. <article-title>Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>103</volume>:<fpage>1529</fpage>&#x02013;<lpage>1534</lpage>.<pub-id pub-id-type="pmid">11257080</pub-id></mixed-citation></ref><ref id="jah32608-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah32608-cit-0020">
<string-name>
<surname>Jensky</surname>
<given-names>NE</given-names>
</string-name>, <string-name>
<surname>Criqui</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Wright</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Wassel</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Brody</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Allison</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Blood pressure and vascular calcification</article-title>. <source>Hypertension</source>. <year>2010</year>;<volume>55</volume>:<fpage>990</fpage>&#x02013;<lpage>997</lpage>.<pub-id pub-id-type="pmid">20176996</pub-id></mixed-citation></ref><ref id="jah32608-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah32608-cit-0021">
<string-name>
<surname>Kandzari</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Brar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Devireddy</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Esler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fahy</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Flack</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Katzen</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Lea</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Leon</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Massaro</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mauri</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Oparil</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>O'Neill</surname>
<given-names>WW</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Rocha&#x02010;Singh</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sobotka</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Svetkey</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Townsend</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Bakris</surname>
<given-names>GL</given-names>
</string-name>. <article-title>Predictors of blood pressure response in the SYMPLICITY HTN&#x02010;3 trial</article-title>. <source>Eur Heart J</source>. <year>2015</year>;<volume>36</volume>:<fpage>219</fpage>&#x02013;<lpage>227</lpage>.<pub-id pub-id-type="pmid">25400162</pub-id></mixed-citation></ref><ref id="jah32608-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah32608-cit-0022">
<string-name>
<surname>Ott</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schmid</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Toennes</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ditting</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Veelken</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Uder</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schmieder</surname>
<given-names>RE</given-names>
</string-name>. <article-title>Central pulse pressure predicts BP reduction after renal denervation in patients with treatment&#x02010;resistant hypertension</article-title>. <source>EuroIntervention</source>. <year>2015</year>;<volume>11</volume>:<fpage>110</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">25982653</pub-id></mixed-citation></ref><ref id="jah32608-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah32608-cit-0023">
<string-name>
<surname>Esler</surname>
<given-names>M</given-names>
</string-name>. <article-title>Renal denervation for treatment of drug&#x02010;resistant hypertension</article-title>. <source>Trends Cardiovasc Med</source>. <year>2015</year>;<volume>25</volume>:<fpage>107</fpage>&#x02013;<lpage>115</lpage>.<pub-id pub-id-type="pmid">25467242</pub-id></mixed-citation></ref><ref id="jah32608-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah32608-cit-0024">
<string-name>
<surname>Palmer</surname>
<given-names>BF</given-names>
</string-name>. <article-title>Renal dysfunction complicating the treatment of hypertension</article-title>. <source>N Engl J Med</source>. <year>2002</year>;<volume>347</volume>:<fpage>1256</fpage>&#x02013;<lpage>1261</lpage>.<pub-id pub-id-type="pmid">12393824</pub-id></mixed-citation></ref><ref id="jah32608-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah32608-cit-0025">
<string-name>
<surname>O'Rourke</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Safar</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Dzau</surname>
<given-names>V</given-names>
</string-name>. <article-title>The Cardiovascular Continuum extended: aging effects on the aorta and microvasculature</article-title>. <source>Vasc Med</source>. <year>2010</year>;<volume>15</volume>:<fpage>461</fpage>&#x02013;<lpage>468</lpage>.<pub-id pub-id-type="pmid">21056945</pub-id></mixed-citation></ref><ref id="jah32608-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah32608-cit-0026">
<string-name>
<surname>DiBona</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Sawin</surname>
<given-names>LL</given-names>
</string-name>. <article-title>Effect of renal denervation on dynamic autoregulation of renal blood flow</article-title>. <source>Am J Physiol Renal Physiol</source>. <year>2004</year>;<volume>286</volume>:<fpage>F1209</fpage>&#x02013;<lpage>F1218</lpage>.<pub-id pub-id-type="pmid">14969998</pub-id></mixed-citation></ref><ref id="jah32608-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah32608-cit-0027">
<string-name>
<surname>DiBona</surname>
<given-names>GF</given-names>
</string-name>. <article-title>Physiology in perspective: the wisdom of the body. Neural control of the kidney</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. <year>2005</year>;<volume>289</volume>:<fpage>R633</fpage>&#x02013;<lpage>R641</lpage>.<pub-id pub-id-type="pmid">16105818</pub-id></mixed-citation></ref><ref id="jah32608-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah32608-cit-0028">
<string-name>
<surname>Linz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hohl</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sch&#x000fc;tze</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mahfoud</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Speer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Linz</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>H&#x000fc;bschle</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Juretschke</surname>
<given-names>HP</given-names>
</string-name>, <string-name>
<surname>Deschend</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Geisel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>R&#x000fc;tten</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>B&#x000f6;hm</surname>
<given-names>M</given-names>
</string-name>. <article-title>Progression of kidney injury and cardiac remodeling in obese spontaneously hypertensive rats: the role of sympathetic innervation</article-title>. <source>Am J Hypertens</source>. <year>2015</year>;<volume>28</volume>:<fpage>256</fpage>&#x02013;<lpage>265</lpage>.<pub-id pub-id-type="pmid">25023205</pub-id></mixed-citation></ref><ref id="jah32608-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah32608-cit-0029">
<string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Tu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>Z</given-names>
</string-name>. <article-title>Renal simplicity denervation reduces blood pressure and renal injuries in an obesity&#x02010;induced hypertension dog model</article-title>. <source>Clin Exp Pharmacol Physiol</source>. <year>2016</year> Aug 25. DOI: <ext-link ext-link-type="doi" xlink:href="10.1111/1440-1681.12661">10.1111/1440&#x02010;1681.12661</ext-link>. [Epub ahead of print].</mixed-citation></ref><ref id="jah32608-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah32608-cit-0030">
<string-name>
<surname>Doltra</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hartmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stawowy</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Goubergrits</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kuehne</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wellnhofer</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gebker</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schneeweis</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schnackenburg</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Esler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fleck</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kelle</surname>
<given-names>S</given-names>
</string-name>. <article-title>Effects of renal denervation on renal artery function in humans: preliminary study</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>:<fpage>e0150662</fpage>.<pub-id pub-id-type="pmid">27003912</pub-id></mixed-citation></ref><ref id="jah32608-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah32608-cit-0031">
<string-name>
<surname>Mahfoud</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Cremers</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Janker</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Link</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Vonend</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Ukena</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Linz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schmieder</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Rump</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Kindermann</surname>
<given-names>I</given-names>
</string-name>. <article-title>Renal hemodynamics and renal function after catheter&#x02010;based renal sympathetic denervation in patients with resistant hypertension</article-title>. <source>Hypertension</source>. <year>2012</year>;<volume>60</volume>:<fpage>419</fpage>&#x02013;<lpage>424</lpage>.<pub-id pub-id-type="pmid">22733462</pub-id></mixed-citation></ref><ref id="jah32608-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah32608-cit-0032">
<string-name>
<surname>Vink</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Boer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Verloop</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Spiering</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Voskuil</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vonken</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hoogduin</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Leiner</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bots</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Blankestijn</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>The effect of renal denervation on kidney oxygenation as determined by BOLD MRI in patients with hypertension</article-title>. <source>Eur Radiol</source>. <year>2015</year>;<volume>25</volume>:<fpage>1984</fpage>&#x02013;<lpage>1992</lpage>.<pub-id pub-id-type="pmid">25595641</pub-id></mixed-citation></ref><ref id="jah32608-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah32608-cit-0033">
<string-name>
<surname>Ott</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Janka</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schmid</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Titze</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ditting</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sobotka</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Veelken</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Uder</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schmieder</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Vascular and renal hemodynamic changes after renal denervation</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2013</year>;<volume>8</volume>:<fpage>1195</fpage>&#x02013;<lpage>1201</lpage>.<pub-id pub-id-type="pmid">23559677</pub-id></mixed-citation></ref><ref id="jah32608-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah32608-cit-0034">
<string-name>
<surname>Ott</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mahfoud</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Schmid</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Toennes</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Ewen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ditting</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Veelken</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ukena</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Uder</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>B&#x000f6;hm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schmieder</surname>
<given-names>RE</given-names>
</string-name>. <article-title>Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension</article-title>. <source>J Hypertens</source>. <year>2015</year>;<volume>33</volume>:<fpage>1261</fpage>&#x02013;<lpage>1266</lpage>.<pub-id pub-id-type="pmid">25923731</pub-id></mixed-citation></ref><ref id="jah32608-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah32608-cit-0035">
<string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Kandzari</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>O'Neill</surname>
<given-names>WW</given-names>
</string-name>, <string-name>
<surname>D'Agostino</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Flack</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Katzen</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Leon</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mauri</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Negoita</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Oparil</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rocha&#x02010;Singh</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Townsend</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Bakris</surname>
<given-names>GL</given-names>
</string-name>. <article-title>A controlled trial of renal denervation for resistant hypertension</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>370</volume>:<fpage>1393</fpage>&#x02013;<lpage>1401</lpage>.<pub-id pub-id-type="pmid">24678939</pub-id></mixed-citation></ref><ref id="jah32608-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jah32608-cit-0036">
<string-name>
<surname>Id</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kaltenbach</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bertog</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Hornung</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hofmann</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Vaskelyte</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sievert</surname>
<given-names>H</given-names>
</string-name>. <article-title>Does the presence of accessory renal arteries affect the efficacy of renal denervation?</article-title>
<source>JACC Cardiovasc Interv</source>. <year>2013</year>;<volume>6</volume>:<fpage>1085</fpage>&#x02013;<lpage>1091</lpage>.<pub-id pub-id-type="pmid">24156968</pub-id></mixed-citation></ref><ref id="jah32608-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jah32608-cit-0037">
<string-name>
<surname>McCambridge</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Witton</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Elbourne</surname>
<given-names>D</given-names>
</string-name>. <article-title>Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects</article-title>. <source>J Clin Epidemiol</source>. <year>2014</year>;<volume>67</volume>:<fpage>267</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">24275499</pub-id></mixed-citation></ref><ref id="jah32608-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jah32608-cit-0038">
<string-name>
<surname>Esler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>B&#x000f6;hm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sievert</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Rump</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schmieder</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Krum</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mahfoud</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Schlaich</surname>
<given-names>M</given-names>
</string-name>. <article-title>Catheter&#x02010;based renal denervation for treatment of patients with&#x000a0;treatment&#x02010;resistant hypertension: 36&#x000a0;month results from the SYMPLICITY HTN&#x02010;2 randomized clinical trial</article-title>. <source>Eur Heart J</source>. <year>2014</year>;<volume>35</volume>:<fpage>1752</fpage>&#x02013;<lpage>1759</lpage>.<pub-id pub-id-type="pmid">24898552</pub-id></mixed-citation></ref><ref id="jah32608-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jah32608-cit-0039">
<string-name>
<surname>Laffin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bakris</surname>
<given-names>G</given-names>
</string-name>. <article-title>Renal denervation: a filed in flux</article-title>. <source>Curr Hypertens Rep</source>. <year>2016</year>;<volume>18</volume>:<fpage>56</fpage>.<pub-id pub-id-type="pmid">27245681</pub-id></mixed-citation></ref></ref-list></back></article>